INDEX TO VOLUME 176

Author Index

Abada, E. T., 505
Abkowitz, J. L., 269
Abramson, O., 1253
Abzug, M. J., 41, 1437
Adair, J. R., 59
Adler, M. W., 183
Agadjanyan, M., 1501
Agin, C. S., 1401
Agostini, H. T., 1
Aguero-Rosenfeld, M., 1029
Ahmad, N., 649
Ahmed, A., 1239
Air, G. M., S62, S66
Aiuti, F., 904
Ajello, G., 1277
Akeda, Y., 822
Åkerlund, K., 1303
Alario, C., 904
Alcaide, F., 1001
Alcendor, D. J., 1476
Alexander, N., 242
Alfieri, C., 1454
Al-Harthi, L., 1175
Allos, B. M., S91, S125, S192, S198, 1105
Alpers, M. P., 242
Alric, L., 1614
Altena, S. A., 1374
Alter, H. J., 586
Altwegg, M., 672
Amato, S. F., 1260, 1313
Ambroggi, M., 637
Ameti, D. I., 1468
Ampel, N. M., 649
Anaissie, E. J., 1579
Anderson, D. J., 941, 960
Anderson, L. J., 1423
Andersson, J., 1303
Andersson, U., 1303
Andréoni, C., 560
Andreu, A., 464
Angarano, G., 1180
Angeloni, A., 541
Aoki, F. Y., 78
Arango-Jaramillo, S., 1168
Arauz-Ruiz, P., 851
Arbeit, R., 1233
Argent, A. C., S139
Arias, M., 1552
Arvin, A. M., 578
Asanovich, K. M., 1029
Aspinall, G. O., S135
Aspöck, H., 1414
Astemborski, J. A., 144, 586
Auer, H., 1414
Aukrust, P., 913
Avila, J. C., 1590
Awad, M. M., 189
Baboo, K. S., 1120
Bader, R. L., 78
Badley, A. D., 1135
Bagarazzi, M. L., 1501
Bagasra, O., 541
Bagby, G. J., 1019
Bagnarelli, P., 801
Bakken, J. S., 1029
Bakker, M., 1383
Bakker, P. J. M., 811
Bakshi, S., 1496
Ballarini, P., 969
Balzarini, J., 1392
Bansal, G., 1215
Barbosa, C., 286
Bardenheier, B., 456
Barditch-Crovo, P., 406
Barnett, S. W., 948
Barrera, L., 637
Barrera, L. F., 1552
Barrett, T. J., 815, 1625
Barthold, S. W., 687
Bartok, A. E., 1225
Baskin, G. B., 374
Batanghari, J. W., 678
Bates, D. W., 1538
Baughman, W., 1277
Beall, B., 177
Bealmear, B., S173
Becich, M. J., 1476
Belisle, J. T., 133
Bell, A. F., 258
Bellon, G., 431
Benach, J. L., 470
Bender, B. S., 273
Benson, L. M., 722
Beretti, J.-L., 1285
Berger, C., 1370
Berger, J., 478
Bergeron, M., 693
Berman, P. W., 384
Bernardi, M. L., 904
Berry, J., 1035
Bessen, D. E., 177
Besser, J. M., 1625
Bewley, K., 445
Bhagani, S., 542
Bianchi, M., 1303
Bilello, J., 1161
Bilker, W. B., 1366
Binz, H., 560, 884
Birx, D. L., 1085
Bistoni, F., 217
Bjerkeli, V., 913
Björk, L., 1303
Björndal, Å., 1180
Blaak, H., 1383
Black, E., 1538
Black, K. M., 1260
Blackbourn, D. J., 948
Blaser, M. J., S91, S103, S198, 1105
Blauvelt, A., 771
Block, S., 445
Bloigu, A., 1100
Blondin, C., 1621
Bloom, B., 1445
Bloomer, C., 84
Boag, F., 103
Bobo, L. D., 1524
Bockarie, F., 242
Bockarie, M., 242
Bodsworth, N. J., 103, 1064
Boeckh, M., 778
Bogdan, I., 693
Boggs, J., 892
Bolin, C. A., 1559
Bolognesi, D. P., 924
Bonagura, V., 1496
Borleffs, J. C. C., 103
Bosch, F. X., 353
Boschini, A., 969
Boschwitz, J. S., 678
Boucher, C. A. B., 398
Boutonnier, A., 431
Bowden, F. J., 289
Boyer, J. D., 1501
Boyle, C. A., S50
Bozzette, S. A., 1225
Bramley, A. J., 1637
Brands, R., S20
Brandt, C., 884
Brasky, K. M., 948
Brathwaite, W., 1397
Brattig, N., 838
Braun, G., 1334
Breinig, M. C., 1462
Breman, J. G., 1058
Brettler, D. B., 118
Brockman, S., 286
Bronowicki, J.-P., 518
Brouillette, W. J., S62
Brown, A. E., 794
Brown, B. W., 578
Brown, D. R., 1141
Brown, K. E., 269
Brown, S., 1269
Brunham, R. C., 1035
Bryan, J. T., 1141
Bryan, T., 545
Bryant, A. E., 189
Burdge, D., 103
Burger, H., 1093
Burkart, T., 526
Burke, D. G., 1080
Burkholder, B. T., 34
Burroughs, A., 1484
Buster, B. L., 1041
Butini, L., 801
Buurman, W. A., 439
Buzby, J. C., S192
Cahill, P., 704
Callahan, C. W., 1652
Cameron, D. N., 1625
Campbell, L. A., 292
Candela, M., 801
Caracciolo, J., 992
Carbone, M., 168
Carey, K. D., 948
Carlesimo, M., 904
Carlone, G. M., 1277
Carnevali, L., 277
Carr, F. J., 59
Carrano, R., 1501
Carter, D., 1590
Casey, R., 1428
Casparian, J. M., 84
Cassone, A., 904
Castellsagué, X., 353
Castiel, P., 1621
Castillo, R. C., 1168
Cate, T. R., S38
Cederna, J., 27
Cenci, E., 217
Centers for Disease Control and Prevention-Bronx Lebanon HIV Serosurvey Team, 1629
Cespedes, J. L., 1590
Chaim, W., 828
Chain, B. M., 755
Chaka, W., 1633
Chalikonda, I., 9
Chandran, B., 84, 94
Chang, I., 78
Chang, L.-Y., 427
Chang, M.-H., 427
Chantelois, J. L., 831
Chapman, B., 807
Chattergoon, M., 1501
Chen, M., 281, 1327
Chen, Y.-H., 492
Cheng, S.-L., 807

Chernoff, D. N., 514, 1388
Cherrington, J. M., 69, 1517
Cheung, T., 892
Chin, D. P., 976
Chou, S., 786
Chou, T.-C., 265
Chouraqui, M., 1378
Chow, L., 693
Christensen, J. P., 151
Christensen, R. B., 876
Christensen, S. B., 1327
Christensson, B., 1096
Christin, L., 1567
Church, P. J., 1644
Cinque, P., 250
Clark, B. D., 1313
Clark, D. R., 649
Clarke, L. M., 286
Clarke, M. J., 1423
Clayson, E. T., 763
Clementi, M., 801
Clements-Mann, M. L., 1428
Cobb, E. K., 948
Cochran, J. B., 168
Cockerill, F. R., III, 722
Cohen, O. J., 924
Cohen, P. S., 1303
Cohn, D. L., 126
Cohn, S., 1397
Colacino, J. M., S66
Colebunders, R., 103
Coleman, R. L., 514
Collazos, J., 1412
Collier, A., 1517
Collins, M. L., 421
Collman, R. G., 1093
Coney, L., 1501
Connolly, A. M., S157
Converse, P. J., 144
Conway, B., 1156, 1388
Cook, J. A., 168
Cook, J. C., 1141
Cook, P. M., 771
Coombs, R. W., 775
Cooper, C., 499
Cooperberg, P., 1388
Cope, A. V., 1484
Corey, L., 94, 775, 892, 1129
Corsi, D., 655
Cortese, J. F., 1590
Corvaïa, N., 560
Cotton, D., 414
Couch, R. B., S38
Couchenour, D., 1215
Couppié, P., 1090
Coutinho, R. A., 112, 665
Cowan, J., 831
Cowart, R. E., 1579
Cox, E., 1129
Cox, N. J., S4, S87
Craib, K. J. P., 798
Crawford, J. T., 976
Critchlow, C. W., 625
Cross, S. M., 1068
Crowe, J. E., Jr., 1428
Crumpacker, C. S., 807
Cundy, K. C., 406
Cusumano, V., 168
Cutright, J. L., 728
Cuzzola, M., 168
Daff, B., 304
Dagan, R., 1253
Dagoro, H., 242
Dailey, P., 1388
Dalhoff, A., 431
Dambrosi, A., 637
Daniel, R. W., 353, 1618
Dankert, J., 196
Danner, S. A., 398, 811
Darouiche, R. O., 227, 1109
Dassy, B., 431
Daum, R. S., 445
Davenny, K., 414
David, J. R., 1649
Davide, J. P., 9
Davidsen, J., 1327
Davidson, B. L., 570
Davis, G. L., 421
De Antoni, A., 899
De Benedittis, M., 277
De Clercq, E., 1392
Deeks, S. G., 514, 1517
Deelder, A. M., 1344
DeGirolami, P., 1233
de Groot, T., 398
DeHertogh, D., 103
de Jong, D., 398
de Kantor, I. N., 637
Dekker, C., 1129
Delbeke, E., 1378
del Giudice, P., 1090
Del Sero, G., 217
DeLuca, D., 649
Denny, F. W., Jr., 992
Detels, R., 1161
de Thé, G., 505
Detmer, J., 421
Deutz, A., 1414
Devine, D. V., 339
de Wolf, F., 665, 811, 1383
Dezfuli, M. G., 1225
Dezube, B. J., 807
Diamond, C., 775
Diamond, R. D., 1567
Diaz-Mitoma, F., 1454
diCorvaía, ee N., 560
Dierich, M. P., 492
Di Fine, M., 969
Di Lonardo, M., 637
Dimber, Z., 242
Dimmock, N. J., 549
Diwan, A., 542
Djimde, A., 1590
Dobard, E., 1293
Dockrell, D. H., 1135
Dodd, R. Y., 1047
Dodson, F., 1491
Doffoel, M., 518
Dogon, A. L., 807
Doms, R. W., 1093
Döring, G., 431
Dormitzer, M., 1215
Doumbo, O. K., 1590
Dowdle, W. R., S69
Dowling, A., 1146
Drew, W. L., 348, 786, 892, 1517
Dubé, M. P., 1225
Dubois, M., 1614
Dudley, D., 859
Duerr, A., 286
Duffaut, M., 1614
Dumler, J. S., 1029
Dummer, S., 1462
Dunlap, K., 728
Dunn, J. P., 790
Durand, D., 1614
Dutly, F., 672
Eastham, J. R., 523
Eastman, D. J., 384
Ebeling, D., 406
Echeverria, P., 1013
Eckels, K. H., 1085
Efron, B., 1146
Eghtesada, S., 273
Eglin, R. P., 1360
Ehrlich, G. D., 1476
Eickhoff, T. C., 311
Eiden, L. E., 1198
Eisenstein, T. K., 183
Elliott, S. L., 1068
Ellner, J. J., 1351
Emerson, S. U., 593
Emery, V. C., 1484
Endtz, H. Ph., S99
Enger, C., 790
Ennis, F. A., 313, 322
Enzensberger, W., 250
Erbelding, E. J., 1397
Erdman, D. D., 760
Ernst, J., 1629
Ertugrul, N., 1401
Espevik, T., 913
Estrada-Franco, J. G., 1590
Evans, A. A., 845
Evans, B. A., 103
Ezzell, R. M., 1313
Faggioni, A., 541
Fairley, C. K., 289
Fan, J., 713
Farthing, M. J. G., 1120
Fauci, A. S., 374, 924
Favorov, M. O., 34
Fehniger, T. E., 1303
Feinberg, J., 892
Feinberg, M. B., 514
Feldman, R. A., 1120
Feltquate, D. M., S50
Fennell, C., 464
Fennelly, G., 1445
Fenoglio, E. D., 331
Fenyö, E. M., 1180
Fernandez, F., 464
Fidel, P. L., Jr., 728
Fikrig, E., 687
Fikrig, S., 1496
Filipenko, D., 1388
Fine, M., 845
Fink, L. M., 924
Fiore, J. R., 1180
Fiorentino, T. R., 177
Fischler, B., 281
Fleming, D. W., 815
Fliss, D. M., 1253
Flock, J.-I., 1096
Flock, M., 1096
Flood, J., 348
Foli, A., 899
Follansbee, S. E., 348, 786
Ford, A., 1579
Forman, S. J., 782
Forrer, R., 672
Fournet, J.-C., 1285
Fournier, J.-M., 431
Fox, C. H., 374
Foxman, B., 828
Fracasso, C., 1180
Francis, D. P., 384
Franco, E., 1597
Francotte, M., 331
Fransen, S., 1156
Fredrickson, T., 362
Freedman, A. R., 1510
Freeman, C. J., 760
Freeman, W. R., 69
Fridey, J., 1468
Friedman, C. R., 478
Frøkjaer, S., 1327
Frøland, S. S., 913
Fryauff, D. J., 1644
Frye, S., 250
Fuchs, K., 1414
Fujimoto, S., 1105
Fujinami, R. S., 258
Fukushima, M., 602
Fuller, M. D., 69
Fung, J., 1491
Gabrielli, A., 801
Galai, N., 308
Gallez-Hawkins, G. M., 782
Galli, M., 1209
Gallia, G. L., 1603
Galloway, D. A., 625
Ganem, D., 775
Gangaidzo, I., 1633
García, L. F., 1552
Garcia-Sastre, A., S45
Garland, S. M., 289
Garvey, J., 348
Gathe, J., 892
Gathmann, I., 1113
Gattei, E., 969
Gaudio, P. A., 1013
Gaytan, A., 533
Ge, Y., 1260, 1313
Gemperli, B., 1113

Généreux, M., 103
Genovese, F., 168
George, H. A., 1141
George, K. S., 1476
Georges, D. L., 807
Gérard, Y., 1090
Gerding, D., 1233
Gershon, A. A., 1072, 1496
Gessain, A., 505
Ghaffari, A., 353
Gheesling, L. L., 1277
Gibble, J. W., 1468
Gibson, F. M., 1510
Gigliotti, F., 1322
Gill, M. J., 78
Gill, V., 1510
Gilligan, P. H., 992
Gilman, R. H., 1584
Ginsburg, K. A., 728
Giral, P., 1621
Glickman, L. T., 206
Glynn, S. A., 1468
Gobert, J.-G., 834
Goddard, E. A., S139
Goedert, J. J., 1618
Goldberg, B., 545
Goldenberger, D., 672
Goldstein, E., 84
Goluszko, P., 158
Gomes, G., 201
Gonnella, R., 541
Goodman, J. L., 1405
Goodman, R., 1233
Goossens, H., 1124
Gordin, F. M., 126
Gordon-Smith, E. C., 1510
Gorse, G., 384
Goshen, S., 1253
Goudsmit, J., 665, 811, 1383
Graham, N. M. H., 144, 1161
Graman, P. S., 1538
Gray, A. M., 384
Grayston, J. T., 292
Grazziutti, M. L., 1579
Greco, G., 948
Green, S., 313, 322
Green, S. W., 269
Green, T. A., 976
Greenberg, D., 1253
Greenough, T. C., 118, 933
Greenwood, B., 1113
Greve, J. M., 523
Griffin, G. E., 1510
Griffiths, P. D., 1484
Gringeri, A., 1180
Grogan, J. L., 1344
Gruber, A., 492
Grundy, J. E., 59
Gruninger, R. P., 992
Gryseels, B., 304
Guentzel, S., 786
Guerra, E. C., 904
Guerrant, R. L., 247
Guerry, P., S122
Guetard, D., 655
Guirao, X., 439
Gunz, A., 672
Guptill, L., 206
Guris, D., 456
Gürr, W., 1334
Gwaltney, J. M., Jr., 523
Haase, A. T., 1198
Hack, C. E., 296
Hadiputranto, H., 1644
Hadler, S. C., 456
Haeffner-Cavaillon, N., 1621
Haeuw, J. F., 560
Hagensee, M. E., 625
Hajjeh, R., 499
Hakenbeck, R., 1001
Hall, W. C., 1215
Hallett, C. A., 649
Halstead, S. B., 1366
Hamilton, A. A., 59
Hampson, A. W., S8
Han, J.-Q., 20
Han, S. N., 273
Hancock, D. D., 815
Hankins, M., 499
Hanna, S. M., 339
Hansen, S., 1641
Hanson, I. C., 414
Hao, Q., S129
Harmsen, A. G., 1322
Harmsen, W. S., 1135
Harnett, N., 1269
Harris, M., 1388
Harris, W. J., 59
Harrison, L. H., 308, 544
Harrison, T. S., 485, 537
Hartleib, J., 984
Hartman, S., 976
Havlir, D. V., 1225
Hawes, S. E., 625
Hawkes, C. A., 794
Hayden, F. G., S56, 1417
Hayek, M. G., 273
Hayes, P., 1510
Hayward, G. S., 1476
Haywood, M., 1113
Hazra, S. K., 530
Hedberg, C. W., 1625
Hedberg, K., 815
Heinzel-Wieland, R., 740
Hellman, J., 1260
Hellmann, N., 1517
Hemming, V. G., 1215
Hendley, J. O., 523
Hendrix, C. W., 406
Hennessy, S., 1366
Henrickson, K. J., 867
Heppner, D. G., 233
Heptonstall, J., 1360
Herbert, S., 431
Herriott, D. E., 815
Herrmann, M., 984
Hershow, R. C., 308, 414
Hestdal, K., 913
Hewlett, I. K., 545
Heyderman, R., 1633
Heymann, D. L., 1058
Hibberd, P. L., 1538
Hickey, S. M., 1239
Hiemstra, P. S., 300, 740
Hilburger, M. E., 183
Hill, A. V. S., 530
Hillyer, G. V., 414
Hinterdorfer, F., 1414
Hirsch, M. S., 265, 510
Hittinger, G., 1378
Ho, M., 1462, 1610
Ho, T. W., S180
Höchli, M., 672
Hodes, D., 1496
Hodzic, E., 687
Hoepelman, A. I. M., 1633
Hoffman, S. L., 1644
Hoffman, T. L., 1093
Hofmann, K. J., 1141
Hoge, C. W., 1013
HogenEsch, H., 206
Hogerman, D., 445
Hogg, R. S., 798
Hohman, P., 1129
Holland, P. V., 34
Holman, R. C., 1423
Holodniy, M., 766
Holte, S., 625
Honda, T., 822
Honkanen, P. O., 1100
Hook, K. K., 331
Hopewell, P. C., 976
Hopkins, R., 499
Horsburgh, C. R., Jr., 126, 976
Horvat, R., 84
Houff, S. A., 1603
Houghton, M., 859
Hounkpatin, S., 838
Hsieh, Y.-H., 1524
Hu, D. J., 1629
Huang, L.-M., 427
Huang, M.-L., 94, 775
Hubbert, N. L., 876
Huddleston, D., 1198
Hudziak, H., 518
Hughes, R. A. C., S92
Huneau, J. F., 834
Hunsmann, G., 250
Hurni, W. M., 1141
Huss, T., 884
Hussey, E. K., 1417
Hutwagner, L., 499
Hyun, P., 242
Iacuzio, D. A., S1
Idänpään-Heikkilä, I., 704
Ieven, M., 1124
Ijdo, J. W., 687
Ilstrup, D. M., 1135
INCAS Study Group, 1388
Inderlied, C. B., 533
Innes, D. J., 523
Innis, B. L., 313, 322, 763
Irwin, K. L., 1629
Isola, N., 637
Izopet, J., 1614
Izu, A., 1129
Jabs, D. A., 790
Jackson, L. A., 292
Jacobs, B. C., S99
Jaffar, S., 1113
Jaffe, H. S., 406, 892, 1517
Jang, S. J., 1491
Jansen, K. U., 1141
Jansen, P. M., 296
Janssen, M., 665
Janssen, R., 1629
Javadian, A., 1501
Jeang, K.-T., 771
Jekic-McMullen, D., 348
Jellum, E., 1641
Jha, A., 1538
Jiles, R. E., 69
Johnson, B. L., 1538
Johnson, D., 992
Johnson, S., 1215, 1233
Jones, J. L., 1413
Jones, M. F., 1135
Jones, S. L., 144
Jordan, M., 992
Jos Frissen, P. H., 811
Joshi, B. H., 545
Joyce, J. G., 1141
Kahn, J., 1517
Kahn, K., 1538
Kalayanarooj, S., 313, 322
Kalayjian, R. C., 1080
Kaldor, J. M., 112
Kanagusuku, P., 1584
Kanegane, C., 254
Kanegane, H., 254
Kapel, N., 834
Kaper, J. B., 1625
Kaplan, E. L., 992
Kaplan, J., 308
Karon, J. M., 632
Karp, A. C., 819
Karron, R. A., 1428
Katow, S., 602
Katz, D. R., 755
Kauffman, H. F., 300, 740
Kaufman, L., 499
Kazatchkine, M. D., 1621
Kazura, J. W., 242
Keadle, T. L., 331
Kedem, H., 678
Kedes, D. H., 775
Keene, W. E., 815
Keep, L. W., 831
Keet, I. P. M., 112, 665
Kehrel, B., 984
Keitel, W. A., S38
Keller, J. J., 196
Kelly, P., 1120
Kemper, C. A., 1225
Kenner, J. R., 1085
Kent, S. J., 1188

Keogh, C. V., 439
Kessler, H., 892, 1175
Keulen, W., 398
Keyserling, H., 445
Khalili, K., 1603
Khan, A. S., 545
Khanna, K. V., 1559
Kharazmi, A., 1327
Kiatpolpoj, S., 313
Kiehl, M., 825
Kienast, J., 825
Kilbourne, E. D., S29
Killgore, G., 1233
King, S. I., 59
Kirchhoff, L. V., 1047
Kiska, D. L., 992
Kiviat, N., 625
Kjaer, S. K., 876
Kleim, J.-P., 1392
Klein, M. B., 1405
Klein, M. R., 665
Kline, B. C., 722
Knecht, H., 1370
Knowlton, D. R., 570
Koelle, D. M., 94
Koenig, S., 1215
Kolberg, J. A., 348, 421
König, A., 1001
Koopmans, M. P. G., 617, 1374
Kopecko, D. J., S189
Kopf, M., 439
Koski, C. L., S169
Kost, R. G., 1129
Kovach, N. L., 269
Köycü, B., 196
Koziel, M. J., 859
Kramer, F., 892
Kramer, L., 655
Kratz-Albers, K., 825
Krause, R. M., 549
Kreiswirth, B. N., 478
Kremsner, P. G., 1344
Kretzschmar, H. A., 250
Krieger, J. N., 775
Krishnan, C., 1269
Krom, R. A. F., 1135
Kunentrasai, N., 313
Kuo, C.-C., 292
Kuramoto, I. K., 34
Kurashige, T., 254
Kurnick, J. T., 1260
Kuroki, S., S129
Kusne, S., 1462
Kuypers, J., 625
Kwiatkowski, D., 530
Laal, S., 133
LaBrecque, D. R., 20, 27
Lafeuillade, A., 804, 1378
Laine, L., 227
Lalezari, J. P., 786, 892, 1517
Lambert, P.-H., 884
La Montagne, J. R., S1
Lamy, P. D., 1517
Landay, A., 1175
Landesman, S., 414
Lane, J. R., 794
Lang, D. R., S91, S198
Lang, R., 1253
Lange, J. M. A., 398, 811
Langenberg, A. G. M., 1129
Lanken, P. N., 1538
Lara, C., 281
LaRussa, P., 1072, 1496
Laskus, T., 1491
Lastovica, A. J., S139
Lau, J. Y. N., 421
Laver, W. G., S66
Laycock, K. A., 331
Leaman, D., 728
Lederman, M. M., 807
Ledur, A., 1621
Lee, A., 292
Lee, A. S.-G., 1125
Lee, C. A., 542
Lee, C.-Y., 427
Lee, P.-I., 427
Lee, S., 545, 892
Leedom, J. M., 1225
Le Hesran, J.-Y., 505
Lehman, E. D., 1141
Leib, S. L., 693
Leiberman, A., 1253
Leiby, D. A., 1047
Leinonen, M., 1100
Lekstrom, J., 1129
Lemon, S. M., 9
Lenes, B. A., 1047
Leonard, D. G. B., 1080
Leone, P., 904
Lesslauer, W., 296
Leung, B., 798
Levitz, S. M., 485, 537
Levy, J. A., 948
Lew, J., 414
Lewis, J. A., 9
Li, C. Y., S180
Li, W., 1517
Li, X., 782
Licitra, C., 499
Liebovitz, E., 1253
Lien, E., 913
Lietman, P. S., 406
Lim, I. H.-K., 1125
Lin, T.-L., 206
Liñares, J., 1001
Linden, P., 1462
Ling, M.-L., 1125
Lisak, R. P., S173
Lisziewicz, J., 899
Liu, C., 578
Liu, Z.-L., 1366
Lo, S. H., 1496
Locher, C. P., 948
Lockman, H. A., 464
Loetscher, H., 296
Lohr, J. A., 992
Loiselle, P. M., 1260, 1313
London, W. T., 845
Longer, C. F., 763
Loomis-Price, L. D., 1085
Lopez, B., 637
Lori, F., 899
Lowe, R. S., 1141
Lowry, D. R., 876
Lowry, S. F., 296, 439
Lowy, D. R., 1076
Lucius, R., 838
Lukasser-Vogl, E., 492
Lüke, W., 250
Luo, C.-C., 1629
Luo, M., S62
Luo, N. P., 1120
Lupo, D., 1629
Lutfey, M., 478
Luzuriaga, K., 643
Lyles, C. M., 586
Lyles, R. H., 1161
Macasaet, M., 286
Maccarini, U., 277
MacGregor, R. R., 1093
Mack, M. E., 570
Mack, P., 374
Maddalena, C. D., 1209
Madigan, J. E., 1029
Madreperla, S. A., 1080
Magnani, M., 655
Magnarelli, L. A., 687
Magne, D., 834
Magnius, L. O., 851
Magyarlaki, M., 698
Mahieux, R., 505
Major, E. O., 1603
Makharia, M. K., 1117
Makhene, M., 1428
Maldarelli, F., 362
Malinoski, F., 445
Mallegol, I., 227
Malone, J. D., 794
Mancuso, G., 168
Mañez, R., 1462
Manion, D. J., 265
Mañoz, B., 1524
Manuel, D. M., 59
Manzin, A., 801
Marchitelli, G., 277
Margolick, J. B., 1161
Margolis, D., 766
Marker, O., 151
Markus, H. Z., 1141
Marousek, G., 786
Marsh, B. J., 543
Martin, L. N., 374
Martin, M. A., 362
Marx, A., 1423
Mascie-Taylor, C. G. N., 530
Mason, C. M., 1293
Mason, P., 1633
Mast, E. E., 34
Matano, T., 362
Mathews, A., 819
Mattes, K. A., 1041
Mattiacci, G., 904
Mátyás, B. T., 760
Mauclère, P., 505
Mayer, K. H., 941, 960
Mazurek, G. H., 976
Mazzola, F., 801
McChesney, M., 1445
McClarty, G., 1035
McClelland, A., 523
McCracken, G. H., Jr., 1239
McCutchan, J. A., 1225
McDonnell, S., 499
McDougal, L., 1001
McGuire, B., 892
McGuire, W., 530
McKay, R. W., 815
McKechnie, N. M., 1334
McKenzie, R., 1129
McKhann, G. M., S180
McNeil, M., 499
McQuain, C., 1370
Meijer, C. J. L. M., 876
Meissler, J. J., Jr., 183
Mencacci, A., 217
Mendelson, J., 78
Merigan, T. C., 1146
Meroni, L., 1209
Merrill, D. P., 265, 510
Mervish, N., 1496
Meshulam, T., 1567
Mesters, R. M., 825
Metcalfe, K., 201
Meulstee, J., S99
Meurice, F., 1072
Meydani, M., 273
Meydani, S. N., 273
Meza, I., 1597
Mfoupouendoun, J., 505
Michaels, M. G., 1476
Mick, R., 1093
Miedema, F., 665
Migliora, P., 277
Millan, J., 505
Miller, C., 1445
Miller, E., 1538
Miller, G., 362
Miller, J. K., 331
Miller, J. S., 1405
Minahara, H., 602
Miner, R. C., 348, 786
Minor, P., 1629
Misawa, N., 1105
Misko, I. S., 1068
Mitros, F. A., 27
Miyagui, J., 1584
Mizokami, M., 421
Modai, J., 103
Mofenson, L. M., 414
Moi, H., 876
Moldawer, L. L., 296
Mole, L., 766
Molitor, T. W., 1559
Mollinedo, R. E., 1590
Monnet, J.-P., 1285
Monos, D. S., S180

Montagnier, L., 655
Montalvo, A., Jr., 1417
Montaner, J. S. G., 798, 1156, 1388
Montefiori, D. C., 924, 1410
Montgomery, R. R., 984
Monti, G., 1209
Monto, A. S., S1, S32
Montroni, M., 655, 801
Moore, J. P., 1410
Moore, R., 1538
Moran, A. P., S115
Morens, D. M., 549
Morin, M. J., S50
Morris, T. S., 593
Mory, R., 1
Moskovitz, B. L., 227
Moussion, F., 1614
Mouzin, E., 1644
Mshar, P., 177
Mudido, P., 807
Mühlemann, K., 526
Mulato, A. S., 1517
Mulders, M. N., 617
Müller, F., 913
Multinational Sorivudine Study Group, 103
Muñoz, N., 353
Murphey-Corb, M., 374
Murphy, B. R., 1428
Murphy, E. L., 1468
Murphy, P. C., 9
Murphy, S. J., 1401
Murphy, T. F., 1247
Murray, H. W., 1117
Murthy, K. K., 948
Musher, D. M., 1401
Musilek, M., 1285
Musser, J. M., 1126
Muster, T., S45
Myers, L. J., 1625
Myerson, D., 778
Nachamkin, I., S106
Nadal, D., 1370
Nader, S., 578
Nagayama, K., 822
Nagle, R., 1584
Nahm, M. H., 698
Nakamura, G. R., 384
Nakamura, M., 1129
Nakatsuji, Y., 586
Nalin, D. R., 9
Nansen, A., 151
Nash, K. A., 533
Nass, C. C., 1468
Nassif, X., 1285
Naylor, S., 722
Nchito, M., 1120
Ndubani, P., 1120
Neeper, M. P., 1141
Neilsen, G. A., 1064
Nelson, C. M., 1405
Nelson, K. E., 586, 1397
Nelson, S., 1019, 1293
Nemeth, A., 281
Nemo, G. J., 1468
Nevo, Y., S154
Newman, B., 1468
Ngui, S. L., 1360
Nguyen, T. N., 560, 884
Niang, M., 304
Niesters, H. G. M., 1124
Nietz, C., 838
Nijhuis, M., 398
Nikkels, A. F., 261
Niland, J. C., 782
Nimmannitya, S., 313, 322
Nisalak, A., 313, 322
Nishimura, M., S129
Nolan, C. M., 748
Nong, S., 485
Nonnenmacher, B., 876
Norder, H., 851
Nordøy, I., 913
Novak, N., 1524
Nowicki, B. J., 158
Nowicki, S., 158
Nowotny, N., 1414
Nukina, M., S129
Nussenzweig, R. S., S45
Nwanyanwu, O. C., 1590
Obayashi, H., S129
Ochnio, J. J., 1610
O'Connell, S., 1360
O'Grady, J., 1215
Oh, M.-d., 510
O'Hanlon, G., S144
Okano, M., 1649
Okeowo, N. P., 1120
Olander, J. V., 698
Oldenburg, H. A., 296
O'Leary, C. P., S144
O'Leary, J., 133
Oliver, C., 1215
Olivo, N., 1629
Olsen, K., 1239
Orentreich, N., 1641
Orito, E., 421
Ortega, Y. R., 1584
O'Shaughnessy, M. V., 798, 1156
Osterholm, M. T., 1625
Ostermann, H., 825
O'Sullivan, D., 201
Pacelli, L., 103
Pachl, C., 514
Padhye, A., 499
Page-Shafer, K. A., 112
Pakker, N. G., 1383
Pal, A., 933
Palache, A. M., S20
Palese, P., S45
Palmer, A. L., 1437
Pan, X.-P., 1366
Panicali, D. L., 118
Pantaleo, G., 374, 924
Papaioakim, M., S180
París, M. M., 1239
París, S. C., 1552
Parsonnet, J., 1538, 1641
Parta, M., 362
Pasarell, L., 499
Patel, R., 1135
Patenaude, P., 1388
Paterson, B., 289
Paterson, G., S144
Patriarca, P. A., S4
Pattey, N., 1285
Patton, C. M., 1105
Pau, C.-P., 1629
Paulus, C. J., 1625
Pauzé, M., 1269
Pavia, A., 1517
Paya, C. V., 1135
Payen, J. L., 1614
Pelemans, H., 1392
Peña, C. A., 819
Penner, J. L., S135
Pepose, J. S., 331
Perino, M. J., 20
Perlman, D. C., 478
Perry, R., 242
Pestronk, A., S154, S157
Peters, C. J., 1058
Peters, D. J., 470
Peters, G., 984
Peterson, P. K., 1559
Pezzotti, P., 969
Pfarr, D. S., 1215
Phair, J. P., 1161
Pham, T., 158
Phillips, A. N., 542
Picerno, I., 655
Pichlmeier, U., 838
Pichyangkul, S., 233
Piedimonte, G., 655
Pienazek, D., 1629
Piepkorn, M., 94
Piérard, G. E., 261
Pikora, C. A., 643
Pilgrim, A. K., 924
Pinder, M., 1113
Pirillo, M. F., 904
Platt, R., 1538
Plotnicky-Gilquin, H., 884
Plowe, C. V., 1590
Poggi, C., 804, 1378
Pogonka, T., 838
Politch, J. A., 941
Poltoratskaia, N., 478
Pomerantz, R. J., 541
Pontesilli, O., 904
Popov, V., 158
Poscher, M. E., 348, 786
Power, U. F., 560, 884
Pozio, E., 969
Prada, J., 1135
Pradinaud, R., 1090
Prince, G. A., 1215
Profizi, N., 804
Pron, B., 1285
Provost, P. J., 9
Puel, J., 1614
Pugatch, D., 643
Purcell, R. H., 593
Pye, S. J., 1068
Qian, K., 421
Quayle, A. J., 960
Quesenberry, P. J., 1370
Quinn, G. C., 478
Quinn, T. C., 414, 544, 1397, 1524
Quispe, H., 1584
Raad, I. I., 1109
Raboud, J., 1156, 1388
Radkowski, M., 1491
Rae, S., 1156, 1388
Ragheb, S., S173
Rakela, J., 1491
Rambaud, C., 1285
Rankin, G. W., Jr., 775
Rappaport, R., 570
Rasmussen, L., 1146
Rasmussen, M. H., 1327
Ratanachu-eke, S., 313
Ratiwayanto, S., 1644
Ratto-Kim, S., 1085
Rausch, D. M., 1198
Rauws, E. A. J., 196
Rayfield, M., 1629
Raymond, N. J., 1277
Read, E. J., 1047
Reddy, V., 976
Redfield, R. R., 1085
Redman, R. L., 578
Reef, S., 499
Rees, J. H., S92
Reeves, M., 1277
Reichmann, P., 1001
Reimerink, J. H. J., 617
Reingold, A. L., 976
Reinhart, T. A., 1198
Reisinger, K., 445
Reis-Lishing, J., 807
Reiss, P., 811
Relman, D. A., 678, 752
Reniero, A., 637
Rennels, M. B., 445
Rentier, B., 261
Respess, R. A., 1629
Rex, J. H., 1579
Reyes-Terán, G., 948
Rezza, G., 969
Ricci, G., 904
Richards, A. L., 1644
Richie, T. L., 1644
Richmond-Crum, S., 542
Riess, G., 1392
Riester, K. A., 414
Riley, L. W., 478
Rinaldo, C. R., Jr., 1161, 1476
Ripich, S., 766
Risdahl, J. M., 1559
Ritacco, V., 637
Roberts, M., S144
Roberts, T., S192

Robertson, V., 1633
Robinson, H. L., S50
Roca, J. F. T., 655
Roden, R. B. S., 1076
Rodrigue, D., 1517
Rodriguez, D. I., 292
Rodríguez, J. I., 1552
Rodriguez-Barradas, M. C., 1401
Roebuck, K. A., 1175
Roesner, M., 1392
Rogan, M. J., 1198
Rogers, T. J., 183
Rojas, M., 1552
Rolles, K., 1484
Romani, L., 217
Rompalo, A. M., 1397
Rood, J. I., 189
Rooney, C. M., 1454
Rose, T. M., 775
Rosenthal, D., 78
Rossi, P., 969
Rostaing, L., 1614
Rostami, A. M., S160
Rotbart, H. A., 1437
Roth, F., 526
Rothman, A. L., 313, 322
Rothstein, E., 445
Rouleau, D., 1156
Rouse, S., 948
Roxas, C., 1584
Roy, S., 530
Royal, W., III., 790
Royce, C., 1113
Rusnak, F., 722
Ryan, M. A. K., 1401
Ryding, U., 1096
Ryschkewitsch, C. F., 1
Saah, A., 1161
Sabin, C. A., 542, 1484
Sacher, R. A., 1468
Sack, D. A., 201
Sack, R. B., 201
Sacks, S. L., 78
Saengkrai, P., 233
Safar, H., 1109
Safrin, S., 892
Saha, B., 530
Saida, T., S129
St. Amand, A. L., 722
Sainte Marie, D., 1090
Sall, S., 304
Salla, R., 505
Sällberg, M., 281
Salomon, N., 478
Salzberger, B., 778
Samanich, K. M., 133
Sambol, S., 1233
Samore, M., 1233
Sánchez, M. P., 760
Sanchez, P., 1397
Sands, K., 1538
Sankilampi, U., 1100
Santoro, J. C., S50
Satishchandran, V., 183
Satoskar, A., 1649
Sattler, F. R., 1225
Sau, P., 1085
Savarino, S. J., 1625
Savary, C. A., 1579
Savatski, L. L., 867
Savelkoul, P. H. M., 1124
Saxe, I., 1445
Scala, E., 541
Schacker, T., 892
Schaffner, A., 672
Schambelan, M., 514
Schechter, M. T., 112, 308, 544, 798
Scheifele, D. W., 1610
Scheld, W. M., 1041
Schiesari, A., 969
Schiller, J. T., 876, 1076
Schlech, W. F., III, 78
Schluger, N., 478
Schmidt, C., 1068
Schmidt, R. A., 1019
Schmidt, W. N., 20, 27
Schmitz, F.-J., 1531
Schoedon, G., 672
Schoenfelder, J. R., 126
Schoening, V. R., 34
Schofield, T. L., 9
Schreiber, G. B., 1468
Schuitemaker, H., 1383
Schuller, W., 1414
Schultz, L. D., 1141
Schulz, T. F., 771
Schulze, I. T., S24
Schulz-Schaeffer, W. J., 250
Schuurman, R., 398
Schwartz, D. H., 384, 1168
Schwartz, J. S., 1538
Schwendinger, M. G., 492
Scopes, J., 1510
Scott, D. A., S183
Seage, G. R., III., 941
See, D., 1225
Seeber, F., 838
Sei, S., 771
Sekulovich, R., 1129
Selik, R. M., 632
Selvarangan, R., 158
Semba, R. D., 790
Sethabutr, O., 1013
Sethi, S., 1247
Shafran, S. D., 78
Shah, A., 1501
Shah, K. V., 353, 1618
Shahabuddin, M., 545
Shapiro, C. N., 34
Sharma, S., 1117
Sharma, U. K., 1168
Shattock, R. J., 1510
Shaw, A. R., 1141
Shayegani, M., 1401
Shen, C., 1035
Shen, L.-P., 348
Shibata, R., 362
Shick, H. E., 1080
Shih, J. W., 586
Shillington, A., 1156
Shim, J., 1233
Shimko, J., 201
Shrestha, K. B., 763
Shrestha, M. P., 763
Siegrist, C.-A., 884
Siemon, C., 362
Silberman, S. L., 807
Silini, E., 277
Silins, S. L., 1068
Silvestri, G., 655
Simberkoff, M. S., 133
Si-Mohamed, A., 1621
Simon, P. M., 704
Sindic, C. J. M., 250
Singer, E. J., 1
Singh, V. P., 1117
Sirianni, M. C., 541
Sitz, K. V., 1085
Sixma, J. J., 984
Skerrett, S. J., 1019
Skundric, D., S173
Slaoui, M., 331
Slater, L., 206
Smacchia, C., 969
Smith, D. E., 273
Smith, I. L., 69
Smith, J. W., 1468
Smith, M. S., 84
Smith, T. F., 1135
Smoak, B. L., 831
Snitbhan, R., 763
Snounou, G., 1113
Snydman, D. R., 1538
Sobel, J. D., 728, 828
Söderquist, B., 1096
Sokol, K., 704
Solforosi, L., 801
Somasundaran, M., 118, 933
Song, H. F., 1168
Sonnenberg, M. G., 133
Sönnerborg, A., 281
Sow, S., 304
Spataro, P., 655
Speck, C., 775
Spector, S. A., 69
Spiller, O. B., 339
Spinillo, A., 277
Spriggs, D., 201
Spruth, M., 492
Sridharan, G., 1168
Stamm, W. E., 464
Stapleton, A. E., 464
Stapleton, J. T., 20, 27
Stead, W. W., 547
Steffansen, B., 1327
Stein, D. S., 1161
Steinberg, S., 1072, 1496
Steinhoff, M., 445
Stelma, F. F., 304
Stephens, D. S., 1277
Stephens, R. S., 713
Sterling, C. R., 1584
Stevens, D. L., 189
Stewart, A., 233
Stewart, D. R., 593
Stoiber, H., 492
Stoner, G. L., 1
Strathdee, S. A., 112, 798
Straus, S. E., 1129
Strebel, P. M., 456
Stricker, R. B., 545
Strickland, G. T., 819
Strickler, H. D., 1618
Strom, B. L., 1366
Stuart, P. M., 331
Studies of Ocular Complications of AIDS (SOCA) in collaboration with AIDS Clinical Trial Group, 50
Stumpf, R. J., 1047
Subianto, B., 1644
Suc, J. M., 1614
Sullam, P. M., 126
Sullivan, J. L., 118, 643, 933, 1370
Summer, W. R., 1293
Sundar, S., 1117
Suntayakorn, S., 313, 322
Sutamihardja, M. A., 1644
Sutton, L., 510
Svare, E. I., 876
Swidsinski, S., 1001
Tabrizi, S. N., 289
Tachdjian, R., 456
Taha, M.-K., 1285
Tamalet, C., 804
Tamburrini, A., 969
Tamura, J. K., 1215
Tang, H. B., 414
Tang, L. L.-H., 1125
Tang, S.-C., 1366
Tang, T., S144
Tanner, J. E., 1454
Tarara, R., 1445
Tassoni, C. J., 1161
Täuber, M. G., 693
Tay, L., 1125
Tay-Kearney, M.-L., 790
Taylor, S. F., 273
Tegtmeier, B. R., 782
Telfer, P., 542
Telford, S. R., III, 687
ten Kate, F. J. W., 196
Tenover, F., 1233
Tenover, F. C., 1001
Tenti, P., 277
Teo, C. G., 1360
Terro, R., 1269
ter Veer, A., 782
Teti, G., 168
That, H. T., 1614
Theander, T. G., 1327
Thelen, V. M., 1625
Thiede, B., 992
Thomas, D. L., 414, 586, 1397

Thomas, M., 103
Thomis, J., 103
Thompson, J., 1428
Thomsen, A. R., 151
Thorne, A., 1388
Tilles, J. G., 1225
Tjhie, J. H. T., 1124
Tjitra, E., 1644
Todd, J., 1388
Tomé, D., 834
Tomee, J. F. C., 300, 740
Tomlinson, A. J., 722
Toole, J., 406, 1517
Topino, S., 541
Török, T. J., 760, 1423
Torre-Cisneros, J., 1462
Torriani, F. J., 1225
Tosato, G., 254
Toth, B., 499
Tournier, P., 560
Tracey, K. J., 1303
Treanor, J. J., 1417
Trebst, C., 250
Truant, A. L., 183
Trujillo, M., 1239
Tsai, T. F., 1366
Tsao, E., 1215
Tucker, L., 941
Tufaro, F., 339
Tuomanen, E., 704
Turner, A. J., 59
Tweten, R. K., 189
Tyrrell, D. L., 78
Tyson, R. W., 1437
Tytgat, G. N. J., 196
Uccini, S., 541
Ugen, K. E., 1501
Uhl, G., 518
Uhl, J. R., 722
Uhrlacher, A., 518
Ulrich, P., 1303
University of Zimbabwe Meningitis Group, 1633
Urdea, M. S., 421
Ursi, D., 1124
Vaccarezza, M., 374
Vago, L., 250
Valenza, A., 801
van Dam, G. J., 1344
Vandenbroucke-Grauls, C. M. J. E., 1124
van den Brule, A. J. C., 876
van der Avoort, H. G. A. M., 617
van der Ende, A., 196
van der Groen, G., 1058
van der Hulst, R. W. M., 196
van der Meché, F. G. A., S99
van der Poll, T., 296, 439
van Doorn, P. A., S99
van Griensven, G. J. P., 112
Van Kessel, K. P. M., 1531
van Leeuwen, R., 398
van Loon, A. M., 617
Vann, V. R., 1080
van Scharrenburg, G. J. M., S20
Van Strijp, J. A. G., 1531
van 't Wout, A. B., 1383
Van Zee, K. J., 296
Varaldo, P. E., 801
Varani, A. R., 904
Varchetta, S., 1209
Vargas, H., 1491
Vaughn, D. W., 313, 322, 763
Vázquez-Prado, J., 1597
Veenhof, C. H. N., 811
Veitch, J., S144
Veldkamp, K.-E., 1531
Venkataraman, L., 1233
Vennari, J. C., 384
Verheul, A., 1633
Verhoef, J., 1531, 1633
Vesentini, N., 277
Vetter, D., 518
Vetter, J.-M., 518
Veugelers, P. J., 112, 665
Vieira, J., 94
Vincent, A., S144
Vincenzi, L., 541
Vinjé, J., 1374
Viramitrachai, W., 313
Visoná, K. A., 851
Visser, L. H., S99
Vlahov, D., 144, 586, 1397
Vogelman, J. H., 1641
Vogt, R. L., 542
von Seidlein, L., 1113
Vriesendorp, F. J., S164
Vuilo, T., 704
Wakiguchi, H., 254
Walboomers, J. M. M., 876
Wald, A., 1129
Walker, B. D., 859
Walker, J. B., 1417
Wan, C.-M., 1366
Wang, B., 1501
Wang, L.-F., 1491
Wang, S., 1567
Wang, S.-C., 1215
Ward, J. W., 632
Ward, R. L., 570
Warren, H. S., 1260, 1313
Watanabe, H., 247
Watanabe, J., 1584
Watkins, W. M., 1590
Watson, D. A., 1401
Watts, N., 1064
Weber, J. T., 1629
Weber, T., 250
Webster, R. G., S14, S50
Weiner, D. B., 1501
Weiss, L., 1621
Welch, D. F., 206
Wengenack, N. L., 722
Wenger, J. D., 1277
West, S., 1524
Wharton, M., 456
Whipple, D. L., 1559
White, J. H., 1637
White, P., 59
White, R., 514
Whitton, J. L., 258
Widjaja, H., 1644
Wierenga, A. T. J., 300
Wiesner, R. H., 1135
Wilcox, C. M., 227
Williams, W. V., 1501
Willison, H. J., S144
Wilson, G., S144
Wilson, J., 1462
Wilson, M. L., 687
Wimalasundera, S. S., 755
Winkler, I., 1392
Winstanley, P. A., 1590
Winther, B., 523
Witherell, H. L., 1641
WITS Study Group, 643
Wolf, N. A., 728
Wolitz, R. A., 1146
Wong, D. K. H., 859
Wong, R. M., 578
Wong, S.-Y., 1125
Wood, R. W., 269
Woods, R., 1215
Woodward, A., 1188
Worlitzsch, D., 431
Worm, A.-M., 876
Wormser, G. P., 1029
Wright, D. J., 1468
Wright, P. F., 1428
Wrin, T., 384
Writer, J. V., 831
Wu, C.-C., 206
Wu, J., 227
Wu, P., 20, 27
Würzner, R., 492
Wynne, B. A., 126
Wysong, D. R., 1567
Xercavins, M., 464
Xiang, C.-F., 1366
Xu, C., 941, 960
Xu, Z.-W., 1366
Yagupsky, P., 1253
Yajko, D. M., 976
Yamaguchi, Y., 602
Yamamoto, K., 822
Yang, X., 1035
Yao, Y.-J., 1366
Yazdanbakhsh, M., 1344
Yedavalli, V. R. K., 649
Yeung, K.-H., 1269
Yeung, K.-H. A., 286
Yi, K., 1247
Yongvanitchit, K., 233
Yoshikawa, T. T., 1053
Young, J. F., 1215
Young, N. S., 269
Yuki, N., S150
Yund, A. J., 1047
Zabaleta, J., 1552
Zaia, J. A., 782
Zala, C., 1156
Zanzot, E. M., 1260
Zappatore, R., 277
Zavala, F., S45
Zavizion, B., 1637
Zehender, G., 1209
Zerboni, L., 578
Zhai, L., 1327
Zhang, D.-J., 1035
Zhang, Y., 687
Zhang, Y.-j., 1180
Zhao, A., 1188
Zhou, J. T., 924
Zhou, J. Y., 924
Zhou, S. Y. J., 794
Zhu, Y.-D., 1445
Zipeto, D., 1146
Zito, E. T., 570
Zolla-Pazner, S., 133, 1411
Zopf, D., 704
Zucconi, R., 969

Subject Index

ABO blood type, recurrent vaginal candidiasis and, 828
Abscess, streptococcal group A, epidemiology, North Carolina, 992
p-Acetylneuraminic acid, for influenza, S62
Acquired immunodeficiency syndrome (*See* Human immunodeficiency virus infection)
Acute immune polyneuropathy, *Campylobacter* and, S154
Acute-phase proteins, in HIV infection, tenidap effects on, 807
Acyclovir
  for herpes simplex virus infections
    failure of, 892
    labial, 78
  for herpes zoster, in HIV infection, 103
  for varicella-zoster virus infection, in HIV infection, 1080
Adefovir dipivoxil, for HIV infection, 406, 1517
Adenoid epithelial cells, intercellular adhesion molecule 1 expression in, 523
Adenovirus 35, pneumonia, outbreak in psychiatric facility, 760
Adherence
  Borrelia burgdorferi, to neural cells, 470
  Entamoeba histolytica trophozoites, 1597
  Staphylococcus aureus, von Willebrand factor and, 984
Adult worm antigen, *Schistosoma haematobium*, response to, 1344
Aging, infectious diseases and, overview, 1053
AIDS (*See* Human immunodeficiency virus infection)
Alveolar macrophages, tumor necrosis factor effects on, in *Legionella pneumophila* infection, rat model, 1019
Alveolar phagocytosis, intraportal lipopolysaccharide effects on, rat model, 1293
Amantadine, for pandemic influenza, S32, S56, S83
Amebiasis, pathogenesis, fibronectin-derived fragments in, 1597
Amphotericin B, for *Candida albicans* infections, T cell response in, mouse model, 217
Ampicillin, for bacterial meningitis, rabbit model, 1239
Amyloid-A, in HIV infection, tenidap effects on, 807
Anal carcinoma, in human papillomavirus infections, in HIV infection, 625
Anemia, in parvovirus B19 infections, in HIV infection, 269
Animal models
  bacteremia
    coagulation prevention in, baboon, 296
    rat, 1313
  bacterial meningitis, rabbit, 1239
  Bartonella henselae infections, cat, 206
  Candida albicans T helper cell response, mouse, 217
  chimeric simian-HIV infections, macaque, 362
  Chlamydia trachomatis antigenic variation, mouse, 713
  Chlamydia trachomatis vaccination, mouse, 1035
  clostridial gas gangrene, mouse, 189
  cryptosporidiosis, mouse, 834
  cytomegalovirus infections in transplantation, baboon, 1476
  endotoxemia, rat, 1313
  enteric bacteria translocation, rat, 1293
  enterovirus infections, in pregnancy, mouse, 41, 1437
  experimental allergic neuritis, rat, S160, S164
  Guillain-Barré syndrome, after *Campylobacter* infections, S144, S160, S164
  hepatitis A virus nonstructural 3C proteinase antibody development, primates, 593
  herpes simplex virus type 1 vaccination, mouse, 331
  human immunodeficiency virus infection
    acute, macaque, 1188
    immunotherapy for, chimpanzee, 1501
    type 2 superinfection, baboon, 948
  human papillomavirus type 11 vaccination, monkey, 1141
  influenza, vitamin E supplementation in, mouse, 273
  Legionella pneumophila infection host defenses, rat, 1019
  leishmaniasis, mouse, 1649
  maternal enterovirus infections, mouse, 1437
  measles virus vaccination, monkey, 1445
  Onchocerca volvulus pathogenesis, rat, 1334
  Plasmodium infection treatments, rodent, 1327
  pneumococcal pneumonia, mouse, 439
  Pneumocystis carinii immunization, mouse, 1322
  respiratory syncytial virus vaccination, 560
    chimpanzee, 1428
    mouse, 884
  septic shock
    morphine induction, mouse, 183
    neonatal, mouse, 168
  simian immunodeficiency virus infection
    treatment with cyclosporine, rhesus monkey, 374
    viral burden and distribution, macaque model, 1198
  Staphylococcus aureus capsular polysaccharide regulation, rat, 431
  streptococcal meningitis, rat, 693
  Streptococcus pneumoniae pneumonia progression, rabbit, 704
  tuberculosis, swine, 1559
  viral infection–lipopolysaccharide interplay, mouse, 151
Anopheles, in *Wuchereria bancrofti* transmission, 242
Anorexia, in *Bartonella henselae* infections, cat model, 206
Antibiotic survival assay, for *Vibrio parahaemolyticus* invasiveness, 822
Antibiotics (*See also specific antibiotics*)
  prophylactic (*See* Prophylaxis)
  resistance to (*See* Drug resistance)
Antibody(ies)
  dengue virus, in early febrile phase, 322
  for disease treatment, 549
  Ehrlichia, early response, 687
  ganglioside, in Guillain-Barré syndrome, after *Campylobacter* infections, S144, S150, S154
  Haemophilus influenzae, in bronchitis, 1247
  hepatitis A virus, assays for, 9
  hepatitis A virus nonstructural 3C proteinase, detection, primate and human models, 593
  hepatitis C virus, negative tests for, in surreptitious infections, 27
  human immunodeficiency virus
    delayed generation, in vertically infected infants, 643
    neutralizing, 924, 1180
  human papillomavirus
    neutralizing, monkey model, 1141
    seroprevalence in homosexual men, 625
    type 16, epidemiology, gender differences in, 876
  interleukin-10, in chronic Epstein-Barr virus infection, 1454
  JC virus, in progressive multifocal leukoencephalopathy, 250
  monoclonal (*See* Monoclonal antibody(ies))
  Mycobacterium tuberculosis 88-kDa antigens, in preclinical tuberculosis, in HIV infection, 133
  neutralizing
    human immunodeficiency virus, 924, 1180
    human papillomavirus, monkey model, 1141

parainfluenza virus, 867
Pneumocystis carinii, species specificity, mouse model, 1322
rotavirus, after vaccination, 570
Streptococcus pneumoniae
cross-reactive, with low opsonophagocytic activity, 698
multiantigen immunoassay for, 526
tubulin, in demyelinating polyneuropathies, S157
in veterinarians, 1414
Antibody-dependent cellular cytotoxicity, in HIV infection, vertically transmitted, 643
Antifungal agents, endogenous, antileukoprotease, 740
Antiganglioside antibodies, in Guillain-Barré syndrome, after *Campylobacter* infections, S144, S150, S154
Antigen(s)
Campylobacter, S122
Campylobacter jejuni, S135
Candida albicans, helper T cell response to, in vaginal challenge, 728
Chlamydia trachomatis, variation, mouse model, 713
cytomegalovirus, assay for, in polyradiculopathy, 348
hemagglutinin-neuramidase protein, parainfluenza virus type 1, characteristics, 867
schizont-associated, *Plasmodium falciparum*, in T cell activation, 233
Antigen reduction assay, for hepatitis A virus antibodies, in vaccine evaluation, 9
Antileukoprotease, in mucosal fungal defense, 740
Antimalarial drugs, in pregnancy, fetal effects, 831
Antimony compounds, interferon-γ with, for visceral leishmaniasis, 1117
Antiretroviral agents (*See also specific drugs*)
for HIV infection
cellular immune response to, 904
lymph node CD4 lymphocytes in, 1378
Antisense-mediated resistance, to measles virus, 258
Antisera
for disease treatment, 549
Escherichia coli J5, 1260
Anti-tubulin antibodies, in demyelinating polyneuropathies, S157
Antiviral agents (*See also specific drugs*)
for pandemic influenza, S32, S56, S83
Apoptosis
hippocampal neurons, in group B streptococcal meningitis, rat model, 693
T cell, in HIV infection, oxidative damage and, 655
Aprotinin, for pandemic influenza, S56
Arbitrarily primed polymerase chain reaction, for *Clostridium difficile*, 1233
Arcobacter, infections, Guillain-Barré syndrome after, S106
Artemether-benflumetol, for malaria, 1113
Arthritis
in human T cell lymphotropic virus infections, 1468
septic, *Staphylococcus aureus*, vs. collagen-binding protein type, 1096
Aspergillus fumigatus
antileukoprotease defense against, 740
conidia, cytokine response to, 1579
pathogenicity, 300
Atherosclerosis, carotid artery, *Chlamydia pneumoniae* isolation in, 292
Axonopathy, in Guillain-Barré syndrome, S99, S180

B cells, JC virus infection, 1603
Baboon organs, transplantation, cytomegalovirus identification in, 1476
Bacille-Calmette-Guérin
in measles vaccination, monkey model, 1445
in tuberculosis vaccination, 748, 1351
Bacteremia
Bartonella henselae, cat model, 206
coagulation prevention in, baboon model, 296
Escherichia coli, interleukin-1 production in, rat model, 1313
Mycobacterium avium complex
in HIV infection, 126
treatment, 1225
Neisseria meningitidis, serogroup C, molecular epidemiology, 1277
prediction rules for, in sepsis syndrome, 1538
Staphylococcus aureus, vs. collagen-binding protein type, 1096
streptococcal group A, epidemiology, North Carolina, 992
Streptococcus pneumoniae, progression, rabbit model, 704
Bacterial meningitis, interleukin-10 effects on, rabbit model, 1239
Bacterial translocation, rat model, 1293
Bancroftian filariasis, transmission, 242
Bartonella henselae, infections, cat model, 206
BBG2Na fusion protein, respiratory syncytial virus, vaccination with, mouse model, 560, 884
Bcg genes, in macrophages, virulent *Mycobacterium tuberculosis* inhibition and, 1552
Benflumetol-artemether, for malaria, 1113
Benzoic acid inhibitors, for influenza, S62
Biopsy, liver, hepatitis C virus RNA detection in, in cryptogenic chronic hepatitis, 27
(9-[2-(Bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine), for HIV infection, 406
BK virus, detection, in human urine, 1618
Bladder
catheters for, antimicrobial-coated, 1109
infections, *Escherichia coli*, virulence factors, 464
Blindness, river
cytokine response in, 838
pathogenesis, rat model, 1334
Bloating, in cyclosporiasis, clinical features vs. histopathology in, 1584
Blood
culture, cytomegalovirus, in HIV infection, 50
hepatitis C virus RNA distribution in, 20, 27
human herpesvirus 8 DNA detection in, in Kaposi's sarcoma, 84
Blood donors, hepatitis E virus epidemiology in, Northern California, 34
Blood type, recurrent vaginal candidiasis and, 828
Blood-brain barrier, *Neisseria meningitidis* penetration, 1285
Bone marrow
Ehrlichia infections, 1405
hemopoiesis in, in HIV infection, 1510
JC virus infections, 1603
transplantation
cytomegalovirus infection in
circulating infected endothelial cells in, 778
viral load in, 782
varicella-zoster virus vaccination in, 578
Bordetella pertussis
infections
treatment, immune globulin for, 549
vaccination, 456
monocyte and macrophage binding to, 678
Borrelia burgdorferi
adherence to neural cells, 470
serologic tests for, costs, in Maryland, 819

Bovine papillomavirus, transmission, 1076
BOX-polymerase chain reaction, for *Streptococcus pneumoniae* conjunctivitis, 1401
Brain, JC virus genotypes in, 1
Bronchitis, chronic, *Haemophilus influenzae*, immune response in, 1247
BZLF1 immediate-early *trans*-activator protein, in Epstein-Barr virus infections, cytotoxic T cell response to, 1068

Caco-2 cells, *Vibrio parahaemolyticus* invasiveness, 822
CagA protein, in *Helicobacter pylori* infections, lymphoma risk and, 1641
Campylobacter
  antigens, S122
  culture, S106
  infections
    Guillain-Barré syndrome development after (*See* Guillain-Barré syndrome, after *Campylobacter* infections)
    microbiologic studies, S106
    Miller-Fisher syndrome after, S99, S150
    serodiagnosis, S106
    typing systems, S106
  vaccination, S183, S189
  virulence factors, S122
Campylobacter jejuni
  antigens, S135
  culture, S106
  epidemiology, S183
  in Guillain-Barré syndrome, 1105
    detection, S125
    heat-stable O serotype, S129
    restriction fragment length polymorphism analysis, S129
  infections
    clinical features, S103, S183
    in developing countries, S103
    epidemiology, S103, S139
    microbiologic studies, S106
    treatment, S103
  lipopolysaccharides
    characteristics, S115, S135
    molecular mimicry with gangliosides, S144, S150
  transmission, S103
  vaccination, S183, S189
  virulence factors, S135
Candida albicans
  antileukoprotease defense against, 740
  HIV binding to, 492
  HIV expression and, in monocytes, 485
  hyphae, destruction, polymorphonuclear neutrophils in, 1567
  vaginal immune response to, 728
Candidiasis
  esophageal, in immunodeficiency, treatment, 227
  T helper cell response in, mouse model, 217
  vulvovaginal, recurrent
    blood type and, 828
    local immunodeficiency in, 728
Capsular polysaccharides
  Staphylococcus aureus
    type 5, carbon dioxide inhibition, 431
    type vs. clinical features, 1096
  Streptococcus pneumoniae
    antibodies to
      impaired opsonophagocytic activity in, 698
      persistence after vaccination, 1100
    multiantigen immunoassay for, 526
Carbon dioxide, in *Staphylococcus aureus* capsular polysaccharide regulation, 431
Carcinoma
  anal, in human papillomavirus infections, in HIV infection, 625
  nasopharyngeal, anti-interleukin-10 antibodies in, 1454
Carotid artery, atherosclerosis, *Chlamydia pneumoniae* isolation in, 292
Carriers, hepatitis B virus, 427
  spontaneous positive-to-negative seroconversion in, 845
Catalase-peroxidase activity loss, in *Mycobacterium tuberculosis*, in isoniazid resistance, 722
Catheter-related infections, urinary, prevention, antimicrobial-coated catheters for, 1109
Cationic surfactant method, for hepatitis C virus RNA detection, 20, 27
CCR-5 chemokine receptor gene, alleles, in HIV infection natural immunity, 1093
CD4 (*See* T cells, CD4)
CD14 molecule, soluble, vs. HIV load, 1621
Cefaclor, for otitis media, 1253
Ceftriaxone, for bacterial meningitis, rabbit model, 1239
Cefuroxime, for otitis media, 1253
Cellular immune response
  Aspergillus fumigatus conidia, 1579
  Bordetella pertussis effects on, 678
  Candida albicans antigen vaginal challenge, 728
  hepatitis C virus infections, in seronegative persons, 859
  HIV infection
    skin testing and, 1085
    in vaccination and/or antiretroviral therapy, 904
  leishmaniasis, mouse model, 1649
  rhinoviruses, 755
  tetanus vaccination, during malaria prophylaxis, 1644
  tuberculosis, 1351
Cephalosporins
  for otitis media, 1253
  resistance to, 1001
  susceptibility breakpoints, 1253
Cerebrospinal fluid
  culture, cytomegalovirus, 348
  cytokine profiles in, in cryptococcal meningitis, in HIV infection, 1633
  JC virus antibodies in, in progressive multifocal leukoencephalopathy, 250
  JC virus genotypes in, 1
  varicella-zoster virus in, in HIV infection, 1080
Cervical neoplasia, human papillomavirus in
  male seropositivity and, 876
  penile DNA in, 353
CGP 56697, for malaria, 1113
Chagas' disease, seroepidemiology, United States blood donors, 1047
Chalcones, for malaria, rodent model, 1327
Chemokine(s), HIV infection progression and, 1168
Chemokine receptor CCR-5 gene, alleles, in HIV infection natural immunity, 1093
Chemotaxis, *Entamoeba histolytica* trophozoites, 1597
Chemotherapy, neutropenia in, sepsis in, interleukin-6 and soluble receptor dynamics in, 825
Chickenpox (*See* Varicella-zoster virus, infections)
Children (*See* Pediatric patients)
Chimeric influenza viruses, in vaccine preparation, S45
Chimeric simian-HIV infections, macaque model, 362
Chlamydia pneumoniae, in carotid artery atherosclerosis, 292
Chlamydia trachomatis

antigenic variation, mouse model, 713
infections, detection, self-administered methods for, 289
trachoma, bacterial load in, in pediatric patients, 1524
vaccination, mouse model, 1035
Chloroquine, prophylactic, tetanus vaccination response during, 1644
Cholera, vaccination, Peru-15, 201
Cidofovir
for herpes simplex virus infections, in HIV infection, 892
resistance to, 69, 786
Cirrhosis, cryptogenic, hepatitis G virus replication studies in, 1491
Clarithromycin, resistance to, 1225
Clostridium difficile, diarrhea, outbreaks, typing in, 1233
Clostridium perfringens, gas gangrene, mouse model, 189
cna gene, collagen-binding protein, *Staphylococcus aureus*, type vs. clinical features, 1096
CNI-1493 (tetravalent guanylhydrazone), cytokine production effects, 1303
Coagulation prevention, in bacteremia, baboon model, 296
Cold sores, treatment with undecylenic acid, 78
Cold-adapted vaccines, influenza, S45
Collagen-binding protein, *Staphylococcus aureus*, type vs. clinical features, 1096
Colonization
streptococci group A, invasive disease from, 177
Streptococcus pneumoniae, prevention with oligosaccharides, rabbit model, 704
Common cold, immunopathology, T cell response in, 755
Complement
in cytomegalovirus virion neutralization, 339
in Schwann cell damage, in Guillain-Barré syndrome, S169
Complement receptor 1, in tumor necrosis factor–erythrocyte binding, 1041
Complement receptor 3, *Staphylococcus aureus* delta-toxin stimulation, 1531
Conidia, *Aspergillus fumigatus*, cytokine response to, 1579
Conjunctivitis, nonserotypeable *Streptococcus pneumoniae*, 1401
Core oligosaccharides, *Campylobacter jejuni*, S115
Cornea, herpes simplex virus infections, vaccination for, 331
Costs
Campylobacter-associated Guillain-Barré syndrome, S192
Lyme disease serologic tests, in Maryland, 819
Crachit, Timothy, skeletal remains, tuberculosis in, 1653
Cranial neuropathy, in Guillain-Barré syndrome, S99
C-reactive protein, in HIV infection, tenidap effects on, 807
Croup, hospitalizations for, epidemiology, 1423
Cryptococcosis, in HIV infection, mortality from, 632
Cryptococcus neoformans
HIV expression and, in monocytes, 485
monocyte activity against, in HIV infection, 537
Cryptogenic cirrhosis, hepatitis G virus replication studies in, 1491
Cryptogenic hepatitis, hepatitis C virus RNA detection in, 27
Cryptosporidiosis
in HIV infection
mortality from, 632
vs. seronegative state, natural history, 969
waterborne, 1120
in immunodeficiency, mouse model, 834
waterborne, 1120
Culture
Campylobacter, S106
cytomegalovirus, 1476
cerebrospinal fluid, 348
in HIV infection, 50
thymus, in T cell generation studies, in HIV infection, 649
Tropheryma whippelii, macrophage deactivation for, 672, 752
Cutaneous leishmaniasis, mouse model, 1649
Cyclosporiasis, clinical features vs. histopathology in, 1584
Cyclosporine, for simian immunodeficiency virus infection, rhesus monkey model, 374
Cystitis, *Escherichia coli*, virulence factors, 464
Cytokines
Aspergillus fumigatus conidia induction, 1579
guanylhydrazone effects on, 1303
in HIV infection
tenidap effects on, 807
vs. viral load, 1621
in viral replication, inhibition by protease inhibitors, 1175
in *Onchocerca volvulus* infections, 838
profiles, in cryptococcal meningitis, in HIV infection, 1633
in Schwann cell damage, in Guillain-Barré syndrome, S169, S173
for tuberculosis, 1351
Cytomegalovirus
baboon vs. human, distinguishing, 1476
culture, 1476
infections
in bone marrow transplantation
circulating infected endothelial cells in, 778
viral load in, 782
drug resistance in, 50, 69
in HIV infection
DNA quantitation in, 1146
mortality from, 632
retinitis, 790
treatment, 50
humanized monoclonal antibody against, 59
after liver transplantation, 1135, 1462, 1484
polyradiculopathy in, diagnosis, 348
multidrug-resistant, 786
recovery, in pelvic inflammatory disease, 286
virions, neutralization, complement in, 339
Cytotoxic necrotizing factor-1, *Escherichia coli*, in prostatitis, 464
Cytotoxic T cells (*See* T cells, cytotoxic; T cells, CD8)

Decay-accelerating factor receptor, in urinary tract infections, 158
Defensins, in mucosal fungal defense, vs. antileukoprotease, 740
Delayed-type hypersensitivity assay, for T cell epitopes, in HIV infection, 1085
Delta-toxin, *Staphylococcus aureus*, in neutrophil oxidative burst stimulation, 1531
Demyelinating polyneuropathies, anti-tubulin antibodies in, S157
Demyelinating polyradiculoneuropathy, inflammatory (*See* Guillain-Barré syndrome)
Dengue virus, infections
clinical features, 313
viremia in, 322
2-Deoxy-2,3-dehydro-*N*-acetyl neuraminic acid, for influenza, S62
2'-Deoxy-2'-fluoroguanosine, for pandemic influenza, S56
Desiccation, human papillomavirus resistance to, 1076
Developing countries, *Campylobacter jejuni* infections in, S103
Dexamethasone, for bacterial meningitis, rabbit model, 1239
Diarrhea
Campylobacter jejuni (*See Campylobacter jejuni*, infections)
Clostridium difficile, outbreaks, 1233
Cryptosporidium parvum, 1120
Cyclospora, clinical features vs. histopathology in, 1584
Escherichia coli
O39:NM, 1625
workshop on, 247

in Guillain-Barré syndrome, S99
Didanosine, for HIV infection
hemopoiesis and, 1510
hydroxyurea with, *pol* gene mutations from, 899
zidovudine and nevirapine with, 1388
Dihydrofolate reductase, *Plasmodium falciparum*, mutations, drug resistance and, 1590
Dihydropteroate synthase, *Plasmodium falciparum*, mutations, drug resistance and, 1590
2,4-Dimethoxy-4'-butoxychalcone, for malaria, rodent model, 1327
Diurnal variation, HIV RNA levels, 514
DNA
Chlamydia trachomatis, in vaccine preparation, mouse model, 1035
cytomegalovirus, quantitation, in HIV infection, 1146
influenza virus, in vaccine preparation, S50
vaccines based on (*See* Vaccination, DNA-based)
DNA analysis
branched chain
for cytomegalovirus polyradiculopathy, 348
for hepatitis G, 421
for HIV RNA, 514, 1161
for cytomegalovirus, baboon vs. human, 1476
random amplified polymorphic, *Campylobacter jejuni*, in Guillain-Barré syndrome, 1105
DNA polymerase, mutations in, cytomegalovirus resistance, 69
Dr fimbriae, *Escherichia coli*, in urinary tract infections, 158
Drug abuse
cryptosporidiosis in, natural history, 969
hepatitis G virus infections in, epidemiology, 586
HIV infection in, syphilis serology in, 1397
Drug resistance
cephalosporins, 1001
cidofovir, 69, 786
clarithromycin, 1225
cytomegalovirus, 50, 69, 786
foscarnet, 50
ganciclovir, 50, 69, 786
4-guanidino-neuAc2en, S66
human immunodeficiency virus, 1392
influenza virus, S66
isoniazid, 722, 1125
lamivudine, 398
measles virus, antisense-mediated, 258
Mycobacterium avium complex, 1225
Mycobacterium tuberculosis, 533
Neisseria gonorrhoeae, 1269
penicillin, 1269
Plasmodium falciparum, mutations and, 1590
praziquantel, 304
pyrimethamine-sulfadoxine, 1590
rifampin, 533
Schistosoma mansoni, 304
Streptococcus, 1001
Streptococcus pneumoniae, 1001
tetracycline, 1269
tuberculosis
Buenos Aires, 637
global, 748
zidovudine, 398, 1392
d4T (stavudine), lamivudine with, for HIV infection, 1156
Dysentery, *Shigella*, epidemiology, Thailand, 1013

Ear, pressure in, in influenza, zanamivir effects on, 1417
Ebola virus and fever
research on, 1058
treatment, humoral immune response in, 549
Eggs, influenza vaccine from, S20
Ehrlichia equi, antigenic diversity, geographic, 1029
Ehrlichiosis
antigenic diversity, geographic, 1029
bone marrow cell infection in, 1405
humoral immune response in, 687
Elderly persons
infectious diseases in, overview, 1053
Streptococcus pneumoniae vaccination in, 1100
Electron microscopy, of *Chlamydia pneumoniae*, in carotid endarterectomy specimen, 292
Electrophoresis, pulsed-field gel
for *Clostridium difficile*, 1233
for streptococci, group A, 992
ELISA (*See* Enzyme-linked immunosorbent assay)
Emerging diseases, humoral immune response in, 549
Encephalitis
Japanese, vaccination, 1366
varicella-zoster virus, in HIV infection, 1080
Encephalomyelitis virus, infections, in pregnancy, mouse model, 41, 1437
Endarterectomy, carotid, specimen from, *Chlamydia pneumoniae* isolation from, 292
Endocarditis, *Staphylococcus aureus*, vs. collagen-binding protein type, 1096
Endoscopy, after *Helicobacter pylori* infection treatment, 196
Endothelial cells, cytomegalovirus-infected, in bone marrow transplantation, 778
Endotoxemia, interleukin-1 production in, rat model, 1313
Endotoxin (*See* Lipopolysaccharide)
Entamoeba histolytica, trophozoites, pathogenic mechanisms, 1597
Enterohemorrhagic *Escherichia coli*, workshop on, 247
Enteroviruses, infections, in pregnancy, mouse model, 41, 1437
Enzyme immunoassays
for hepatitis E virus, 34
for Lyme disease, costs, in Maryland, 819
for pneumococcal antibodies, after vaccination, 1100
Enzyme-linked immunosorbent assay
for *Campylobacter*, S106
for hepatitis A virus nonstructural 3C proteinase, primate and human models, 593
for *Mycobacterium tuberculosis* 88-kDa antigen, in preclinical disease, in HIV infection, 133
for parainfluenza virus type 1 hemagglutinin-neuramidase protein, 867
for *Streptococcus pneumoniae* antibodies, 698
Epidemics
influenza (*See* Pandemic influenza)
multidrug-resistant tuberculosis, global, 748
Epidemiology (*See also* Outbreaks)
adenovirus 35 pneumonia, in psychiatric facility, 760
Campylobacter jejuni infections, S103, S183
South Africa, S139
cephalosporin resistance, global, 1001
Chagas' disease, United States blood donors, 1047
croup hospitalizations, 1423
cryptosporidiosis
Italy, 969
Zambia, 1120
Ebola virus, 1058
Escherichia coli infections
enteroinvasive, Thailand, 1013

O157:H7, Oregon, 815
O39:NM, Minnesota, 1625
gastroenteritis, small round-structured viruses in, The Netherlands, 1374
Guillain-Barré syndrome, after *Campylobacter* infections, S92, S129, S139, S198
hepatitis A virus infections, Vancouver schoolchildren, 1610
hepatitis B virus, Central America, 851
hepatitis C virus infections, HIV infection with, Hawaii, 542
hepatitis E virus
Nepal, 763
Northern California blood donors, 34
hepatitis G virus, injecting drug users, 586
human herpesvirus 8 infection, 771
human immunodeficiency virus infection
ethnicity in, 794
primary, in homosexual men, 112
type A, New York, 1629
human papillomavirus DNA, Colombia and Spain, 353
human papillomavirus type 16 antibodies, gender differences in, 876
human T cell lymphotropic virus type I, central Africa, 505
infectious diseases, in human T cell lymphotropic virus infections, 1468
influenza (*See* Influenza, epidemiology; Pandemic influenza)
JC virus genotypes, 1
Mycobacterium tuberculosis, C strain (drug-susceptible), New York City, 478
Neisseria meningitidis, Atlanta, Georgia, 1277
Plasmodium falciparum pyrimethamine-sulfadoxine resistance, 1590
polioviruses, The Netherlands, 617
rubella virus E1 gene, East Asia, 602
shigellosis, polymerase chain reaction for, Thailand, 1013
sporotrichosis, tree nursery workers, 499
streptococcal infections, group A, North Carolina, 992
Streptococcus pneumoniae conjunctivitis, 1401
swine influenza, veterinarians, 1414
Trypanosoma cruzi, United States blood donors, 1047
tuberculosis, multidrug-resistant
global, 748
in HIV infection, Buenos Aires, 637
Epithelial cells, adenoid, intercellular adhesion molecule 1 expression in, 523
Epstein-Barr virus
infections
chronic active
anti-interleukin-10 antibodies in, 1454
interleukin-10 production in, 254
immediate-early *trans*-activator protein BZLF1 in, cytotoxic T cell response to, 1068
in liver transplantation, lymphoproliferative disease in, 1462
latent membrane protein-1 mutations, 1370
Eructation, in cyclosporiasis, clinical features vs. histopathology in, 1584
Erythrocytes
hepatitis C virus RNA in, 20
tumor necrosis factor binding to, 1041
Escherichia coli
bacteremia
coagulation prevention in, baboon model, 296
interleukin-1 production in, rat model, 1313
enterohemorrhagic, workshop on, 247
enteroinvasive, epidemiology, Thailand, 1013
infections
O157:H7, foodborne, 815
O39:NM, 1625
urinary tract, virulence factors in, 158
J5, antiserum against, 1260
prostatitis, virulence factors, 464
Esophagus, candidiasis, in immunodeficiency, treatment, 227
Ethambutol, for *Mycobacterium avium* complex bacteremia, 1225
Ethnicity, in HIV infection epidemiology, 794
Exercise, in pregnancy, enterovirus infections and, mouse model, 41
Experimental allergic neuritis, rat model, S160, S164
Eye
herpes simplex virus infections, vaccination for, mouse model, 331
retinal pathology in, from *Onchocerca volvulus* antigens, rat model, 1334

Fasciitis, necrotizing, streptococcal group A, epidemiology, North Carolina, 992
Fetus, maternal enterovirus infection effects on, mouse model, 1437
Fever
in *Bartonella henselae* infections, cat model, 206
in dengue infection, viremia and, 322
in HIV seroconversion, prognosis and, 112
Fibronectin degradation products, in *Entamoeba histolytica* trophozoite pathogenicity, 1597
Filariasis, *Wuchereria bancrofti*, transmission, 242
Filoviruses, research on, 1058
Flagella and flagellins, *Campylobacter*, S122
Flatulence, in cyclosporiasis, clinical features vs. histopathology in, 1584
FLRGRAYGL peptide, in immediate-early *trans*-activator protein BZLF1, cytotoxic T cell response to, 1068
Fluconazole, for candidiasis
esophageal, in immunodeficiency, 227
T cell response in, mouse model, 217
Fluorescent treponemal test, for syphilis, in HIV infection, false-negative results, 1397
Fomites, human papillomavirus transmission in, 1076
Foodborne diseases, *Escherichia coli* infections
enterohemorrhagic, workshop on, 247
O157:H7, 815
O39:NM, 1625
Foscarnet
for cytomegalovirus retinitis, 50
resistance to, 50
for varicella-zoster virus infection, in HIV infection, 1080
Free radicals
in *Candida albicans* hyphae destruction, 1567
formation, *Staphylococcus aureus* delta-toxin stimulation, 1531
T cell damage from, in HIV infection, 655
Fungal infections (*See also specific infections*)
antileukoprotease defense against, 740
bacteremia, prediction rules for, 1538
in human T cell lymphotropic virus infections, 1468
Fusion-inhibition assay, for respiratory syncytial virus monoclonal antibody activity, 1215

G fusion protein BBG2NA, response to, in respiratory syncytial virus vaccination, mouse model, 560
Gait disturbance, in human T cell lymphotropic virus infections, 1468
Ganciclovir
for cytomegalovirus infections
in bone marrow transplantation, 782
retinitis, 50
resistance to, 50, 69, 786
for varicella-zoster virus infection, in HIV infection, 1080

Gangliosides, antibodies to, in Guillain-Barré syndrome, after *Campylobacter* infections, S144, S150, S154
Gas gangrene, clostridial gas gangrene, mouse model, 189
Gastritis, *Helicobacter pylori*, recurrence rate after treatment, 196
Gastroenteritis
Vibrio parahaemolyticus, virulence factors, 822
viral, epidemiology, The Netherlands, 1374
Gastrointestinal system, gram-negative bacteria release from, morphine induction of, mouse model, 183
GB virus C infection (hepatitis G)
chronic, treatment, 421
epidemiology, in injecting drug users, 586
transmission, mother-to-infant, 281
Genital tract
herpes simplex virus infections, vaccination, 1129
virus recovery from, in pelvic inflammatory disease, 286
Glioma cells, *Borrelia burgdorferi* adherence to, 470
Glucose transport, in cryptosporidiosis, in immunodeficiency, mouse model, 834
β-Glucuronidase, impaired production, in HIV infection, 537
Glycoprotein(s), herpes simplex virus type 2, in immunotherapy, 1129
Glycoprotein D subunit vaccine, herpes simplex virus type 1, mouse model, 331
Glycoprotein UL75, cytomegalovirus, monoclonal antibody binding to, 59
Glycosylation, hemagglutinin, in influenza virus mutation, S24
GM_1 antiganglioside antibodies, in Guillain-Barré syndrome, after *Campylobacter* infections, S144, S150, S154
Gonorrhea, detection, self-administered methods for, 289
GQ_{1b} antiganglioside antibodies, in Guillain-Barré syndrome, after *Campylobacter* infections, S144, S150
Gram-negative organisms
bacteremia, prediction rules for, 1538
sepsis, morphine induction, mouse model, 183
Gram-positive organisms, bacteremia, prediction rules for, 1538
Granulocyte(s), *Ehrlichia* infections, 1405
Granulocyte-macrophage colony-stimulating factor
Aspergillus fumigatus conidia induction, 1579
in *Onchocerca volvulus* infections, 838
4-Guanidino-neuAc2en, resistance to, S66
Guanylhydrazone, cytokine production effects, 1303
Guillain-Barré syndrome
after *Arcobacter* infections, S106
axonopathy in, S99, S180
after *Campylobacter* infections
animal models, S144, S160, S164
antiganglioside antibodies in, S144, S150, S154
anti-tubulin antibodies in, S157
association, S125
Campylobacter jejuni strains in, 1105
Campylobacter vaccines and, S183, S189
clinical features, S92, S99, S154
cytokines in, S173
diagnosis, S198
economic burden, S192
epidemiology, S92, S129, S139, S198
evidence for, S125
human leukocyte antigens and, S92, S180
infection characteristics and, S103
microbiologic studies, S106, S198
pathogen characteristics and, S115, S122, S135
pathogen isolation in, S129
pathogenesis, S198
P_2-reactive T cells in, S160
risk factors for, S125
Schwann cell damage in, S169, S173
severity, S125
in South Africa, S139
subgroups, S99
surveillance for, S198
cranial neuropathy form, S99
motor form, S99
rat model, S160, S164
Schwann cell damage in, S169, S173
sensory form, S99
subgroups, S99
from swine flu vaccination program, S69

Haemophilus influenzae
bronchitis, immune response in, 1247
meningitis, interleukin-10 effects on, rabbit model, 1239
HBY 097, for HIV infection, zidovudine and lamivudine with, 1392
HeLa cells
Escherichia coli virulence factor action on, 158
measles virus antisense-mediated resistance in, 258
Helicobacter pylori, infections
gastric lymphoma risk in, 1641
treatment, reinfection rate after, 196
Helper T cells (*See* T cells, CD4; T cells, helper)
Hemagglutinin
DNA of, in influenza vaccine preparation, S50
influenza virus, mutations affecting, S24
Hemagglutinin-inhibition assay, for parainfluenza virus type 1 hemagglutinin-neuramidase protein, 867
Hemagglutinin-neuramidase protein, parainfluenza virus type 1, characteristics, 867
Hemodialysis, hepatitis C virus infection in, treatment with interferon-α, 1614
Hemolysin, *Escherichia coli*, in prostatitis, 464
Hemophilia, HIV infection in, cytotoxic T cells in, 118
Hemopoiesis, impaired, in HIV infection, 1510
Hemorrhagic fever, dengue
clinical features, 313
viremia in, 322
Hepatitis, cryptogenic, hepatitis C virus RNA detection in, 27
Hepatitis A virus
infections, epidemiology, Vancouver schoolchildren, 1610
nonstructural 3C proteinase, antibodies to, detection, primate and human models, 593
vaccination
antibody detection after, primate and human models, 593
evaluation, 9
in HIV infection, 1064
Hepatitis B virus
epidemiology, Central America, 851
genotypes, Central America, 851
infections, chronic, treatment, interferon-α, 845
mutations in
in carrier children, 427
S gene, vaccine failure from, 1360
vaccination
failure, 1360
mutations after, 427
Hepatitis C virus
infections
in hemodialysis, treatment with interferon-α, 1614
HIV infection with
epidemiology, Hawaii, 542

vertical transmission, 414
T cell response in, in seronegative persons, 859
RNA
detection
with negative antibody tests, 27
in peripheral blood mononuclear cells, 1209
distribution in blood and blood cell fractions, 20
transmission, to spouses, 518
Hepatitis E virus, infections
epidemiology
Nepal, 763
Northern California blood donors, 34
risk factors for, 34
Hepatitis G virus (GB virus C)
infections
chronic, treatment, 421
in cryptogenic cirrhosis, viral replication studies in, 1491
epidemiology, in injecting drug users, 586
replication site for, 1491
Herpes simplex virus
genital, vaccination, 1129
infections
in HIV infection
treatment, 892
viral load and, 766
labial, treatment with undecylenic acid, 78
recovery, in pelvic inflammatory disease, 286
type 1, vaccination, mouse model, 331
Herpes zoster (*See* Shingles)
Heteropolymers, monoclonal antibody-based, in tumor necrosis factor binding to erythrocytes, 1041
*Hin*dIII restriction enzyme analysis, for *Clostridium difficile*, 1233
Hippocampus, neuronal apoptosis in, in group B streptococcal meningitis, rat model, 693
Histoplasmosis, in HIV infection, mortality from, 632
Host defenses
in *Chlamydia trachomatis* infections, in pediatric patients, 1524
intraportal lipopolysaccharide effects on, rat model, 1293
in *Legionella pneumophila* infections, tumor necrosis factor depletion and, rat model, 1019
in leishmaniasis, mouse model, 1649
Human granulocytic ehrlichiosis
antigenic diversity, geographic, 1029
bone marrow cell infection in, 1405
humoral immune response in, 687
Human herpesvirus 6, infections, after liver transplantation, 1135
Human herpesvirus 8
absence, in HIV infection, 775
infections
epidemiology, 771
in HIV infection, 84, 94, 541, 771
Human immunodeficiency virus (type 1)
Candida albicans binding to, 492
cyclosporine effects on, in vitro, 374
distribution, in lymphoid tissue, 804, 1388
mutations, in didanosine-hydroxyurea combination therapy, 899
neutralization assay for, 1410
poliomyelitis vaccine contamination with, 545
replication, inhibition, 1175
RNA
measurement, in progression prediction, 1161
temporal variation in, 514
in semen
distribution among cells, 960
factors affecting, 941
subtypes, epidemiology, New York, 1629
Human immunodeficiency virus (type 2), superinfection with, baboon model, 948
Human immunodeficiency virus infection (type 1)
acute, macaque model, 1188
anal carcinoma in, human papillomavirus and, 625
asymptomatic, with low CD4 cell counts, 665
candidiasis in, esophageal, treatment, 227
cellular immune responses in, 1085
cryptococcosis in
meningitis, 1633
mortality from, 632
cryptosporidiosis in
mortality from, 632
natural history, 969
waterborne, 1120
cytomegalovirus infections in
mortality from, 632
prophylaxis for, 786
retinitis, 50, 790, 1146
treatment, 50
cytotoxic T cells in, 118
in elderly persons, 1053
encephalitis in, varicella-zoster virus, 1080
epidemiology
ethnicity in, 794
primary, in homosexual men, 112
esophageal candidiasis in, treatment, 227
in hemophilia, type 1–specific cytotoxic T cells in, 118
hemopoiesis in, 1510
hepatitis A virus vaccination in, 1064
hepatitis C virus infection in
epidemiology, Hawaii, 542
vertical transmission, 414
herpes simplex virus infection in
treatment, 892
viral load and, 766
herpes zoster in, treatment, 103
histoplasmosis in, mortality from, 632
human herpesvirus 8 absence in, 775
human herpesvirus 8 DNA detection in, 84, 94, 541
human herpesvirus 8 infection in, 771
human papillomavirus seroprevalence in, 625
human T cell lymphotropic virus
type I with, 543
type II with, 308
humoral immune response in, 549
in injecting drug users, cryptosporidiosis in, 969
isosporiasis in, mortality from, 632
Kaposi's sarcoma in, human herpesvirus 8 DNA detection in, 84, 94, 541
leukoencephalitis in, varicella-zoster virus, 1080
long-term nonprogressors
antibody neutralizing activity in, 1180
CD4 cell counts, 665
chemokines and, 1168
neutralizing antibodies in, 924
phenotypes in, 933
low CD4 cell counts in, asymptomatic, 665
lymphocyte oxidative damage in, 655
meningitis in
Cryptococcus neoformans, 1633
varicella-zoster virus, 1080

monocyte anticryptococcal activity in, 537
in monocytes, pathogen effects on, 485
mortality in
from opportunistic infections, 632
prediction, 1161
RNA levels after seroconversion and, 798
mycobacterial infections in, nontuberculous, mortality from, 632
Mycobacterium avium complex infections in
genotyping, 976
prophylaxis, 126
treatment, 1225
natural history
vs. neutralizing antibody response, 924
RNA levels in, 794
natural immunity toward, 1093
nonprogressive (*See subhead*: long-term nonprogressors)
opportunistic infections in, mortality from, 632
parvovirus B19 infections in, anemia in, 269
in pediatric patients, varicella-zoster virus infections in, 1496
peripheral blood T cell generation capacity in, 649
phenotypes, vs. progression, 933
pneumocystosis in, mortality from, 632
primary
cytopathic differences in, 933
epidemiology and prognosis, in homosexual men, 112
neutralizing antibodies in, 924
prognosis
predictive methods for, 1161
primary, in homosexual men, 112
type 1–specific cytotoxic T cells and, 118
progression
vs. CD4 cell counts, 665
vs. phenotype, 933
predictive methods for, 1161
RNA levels after seroconversion and, 798
progressive multifocal leukoencephalopathy in
humoral immune response in, 250
JC virus genotypes in, 1
lymphocyte infection in, 1603
mortality from, 632
prophylaxis, immunotherapy for, 549
radiculomyelitis in, varicella-zoster virus, 1080
resistance in, 398
chemokines in, 1168
retinitis in, cytomegalovirus, 50, 790, 1146
RNA
epidemiology, ethnicity in, 794
after seroconversion, prognostic value, 798
seroconversion in
RNA levels after, mortality and, 798
symptomatic, in homosexual men, 112
simian virus 40 detection studies in, 1618
skin tests for, 1085
syphilis in, false-negative serologic test results in, 1397
T cell responses in, macaque model, 1188
toxoplasmosis in, mortality from, 632
transmission
factors affecting, 941
natural resistance to, 1093, 1168
vertical
antibody-dependent cellular cytotoxicity in, 643
with hepatitis C, 414
treatment, 398 (*See also* Didanosine; Zidovudine)
adefovir dipivoxil, 406, 1517
in advanced disease, 1156
advanced stage, 1156
cellular immune response to, 904
combination, 510, 899, 1156, 1388, 1392
drug interactions in, 265
immune globulin, 913
immunotherapy, chimpanzee model, 1501
interferon-α2a, 811
lymph node CD4 lymphocytes in, 1378
sequential vs. simultaneous combinations in, 510
tenidap, 807
tuberculosis in, 1351
detection methods, 144
multidrug-resistant, 637, 748
nosocomial, 637
Mycobacterium avium complex susceptibility in, 1412
preclinical, antibody detection in, 133
type A, epidemiology, New York, 1629
type 1–specific cytotoxic T cells in, 118
vaccination
cellular immune response in, 904
clinical trials, 384
skin testing in, 1085
varicella-zoster virus infections in, 261, 1080
in pediatric patients, 1496
viral load in
cellular vs. peripheral blood, 1383
vs. chemical mediator levels, 1621
vs. cytotoxic T cell levels, 118
herpes simplex virus infection effects on, 766
immune globulin effects on, 913
lymph nodes vs. plasma, 1388
in lymphoid tissue compartments, 804
plasmapheresis effects on, 801
prognosis prediction and, 1161
vs. progression, 665
temporal changes in, 1383
Human immunodeficiency virus infection–simian immunodeficiency virus chimera, macaque model, 362
Human leukocyte antigens, in Guillain-Barré syndrome, after *Campylobacter* infections, S92, S180
Human papillomavirus
capsid antibodies to, seroprevalence in homosexual men, 625
in cervical neoplasia, epidemiology, Colombia and Spain, 353
desiccation resistance, 1076
DNA, penile, cervical neoplasia related to, 353
infections, latent, in pregnancy, 277
type 11, vaccination, monkey model, 1141
type 16, antibodies to, epidemiology, gender differences in, 876
Human T cell lymphotropic virus type I
diseases associated with, 1468
epidemiology, central Africa, 505
HIV infection with, 543
Norwegian scabies in, 1090
Human T cell lymphotropic virus type II
diseases associated with, 1468
HIV infection with, progression, 308
Humoral immune response
emerging diseases, 549
human granulocytic ehrlichiosis, 687
human immunodeficiency virus infection, 549
neutralizing antibodies in, 924
type 2, baboon model, 948
progressive multifocal leukoencephalopathy, 250

Hydroceles, in *Wuchereria bancrofti* infections, 242
Hydroethydine intracellular oxidation, in T cell damage, in HIV infection, 655
Hydroxyurea, for HIV infection, didanosine with, *pol* gene mutations from, 899
Hyperemia, reactive, in cyclosporiasis, clinical features vs. histopathology in, 1584
Hypersensitivity
  delayed-type, in HIV skin testing, 1085
  to lipopolysaccharide, in asymptomatic viral infections, mouse model, 151
Hyphae, *Candida albicans*, destruction, polymorphonuclear neutrophils in, 1567

Immediate-early *trans*-activator protein BZLF1, in Epstein-Barr virus infections, cytotoxic T cell response to, 1068
Immune globulin
  for emerging diseases, 549
  for Guillain-Barré syndrome, S99
  hepatitis A virus, vs. hepatitis A inactivated vaccine, 9
  for HIV infection, 913
Immune response (*See also* Cellular immune response; Humoral immune response)
  aging and, infectious diseases and, 1053
  clostridial toxin effects on, mouse model, 189
  cytomegalovirus virion neutralization, 339
  Haemophilus influenzae, in chronic bronchitis, 1247
  hepatitis A virus vaccination, in HIV-infected and non–HIV-infected homosexual men, 1064
  lepromatous leprosy, 530
  local, in vulvovaginal candidiasis, 728
  pandemic influenza, S76
  pneumococci, mouse model, 439
  Pneumocystis carinii, mouse model, 1322
  in respiratory syncytial virus vaccination, mouse model, 560
  tuberculosis, 1351
Immunization (*See* Vaccination)
Immunoblot assay, for *Haemophilus influenzae* antibodies, 1247
Immunodeficiency (*See also* Human immunodeficiency virus infection; Transplantation)
  candidiasis in, treatment, 227
  cryptosporidiosis in, mouse model, 834
  in human T cell lymphotropic virus infections, 1468
  Norwegian scabies in, 1090
Immunoglobulin E, antischistosome, after *Schistosoma haematobium* infections, 1344
Immunoglobulin G, binding to *Escherichia coli* J5, 1260
Immunoglobulin G4, antischistosome, after *Schistosoma haematobium* infections, 1344
Immunoglobulin–tumor necrosis factor receptor fusion protein, in coagulation prevention, baboon model, 296
Immunohistochemistry, *Chlamydia pneumoniae*, in carotid endarterectomy specimen, 292
Immunoprecipitation assay, for hepatitis A virus antibodies, in vaccine evaluation, 9
Immunotherapy
  for emerging diseases, 549
  for genital herpes simplex virus infections, 1129
  for HIV infection, chimpanzee model, 1501
  for tuberculosis, 1351
Impetigo, streptococci group A, invasive disease from, 177
Indinavir, for HIV infection, drug interactions, 265
Infectious mononucleosis
  anti-interleukin-10 antibodies in, 1454
  immediate-early *trans*-activator protein BZLF1 in, cytotoxic T cell response to, 1068
  viral mutations in, 1370
Inflammatory demyelinating polyradiculoneuropathy, acute (*See* Guillain-Barré syndrome)
Influenza
  epidemiology (*See also* Pandemic influenza)
    hemagglutinin glycosylation and, S24
  otologic manifestations, zanamivir effects on, 1417
  pandemic (*See* Influenza, vaccination; Pandemic influenza)
  swine
    epidemiology, veterinarians, 1414
    vaccination program for, S69
  vaccination
    adjuvants for, S38
    attenuated, S45
    chimeric viruses in, S45
    with cold-adapted strains, S45
    DNA-based, S50
    evolution, S38
    failure in 1947, S29
    Guillain-Barré syndrome from, S69
    hemagglutinin glycosylation and, S24
    immunomodulators with, S38
    inactivated, S38
    live, S45
    with malarial CD T cell epitope, S45
    mucosal administration, S38
    novel vaccines and vectors for, S45
    in pandemic control, S32, S80
    research on, S80
    subunit, S20
    swine flu program, S69
    utilization priorities, S32, S80
  vitamin E supplementation in, mouse model, 273
Influenza virus
  genetically engineered, in vaccine preparation, S45
  mutations, S14
    glycosylation effects on, S24
  neuraminidase, inhibitors, S62
  resistance in, S66
  transmission, interspecies, S14
  virulence, S29
Intercellular adhesion molecule 1, on adenoid epithelial cells, 523
Interferon(s), in Schwann cell damage, in Guillain-Barré syndrome, S169, S173
Interferon-α
  for hepatitis B virus infections, chronic, 845
  for hepatitis C virus infections, in hemodialysis, 1614
  for hepatitis G virus infections, 421
Interferon-α2a, for HIV infection, 811
Interferon-γ
  in antifungal therapy, mouse model, 217
  Aspergillus fumigatus conidia induction, 1579
  guanylhydrazone effects on, 1303
  in leishmaniasis, mouse model, 1649
  in lipopolysaccharide hypersensitivity, in asymptomatic viral infections, mouse model, 151
  in meningitis, *Cryptococcus neoformans*, in HIV infection, 1633
  Plasmodium falciparum antigen stimulation, 233
  in pneumococcal pneumonia, mouse model, 439
  in rhinovirus infections, 755
  therapeutic

pentavalent antimony compounds with, for visceral leishmaniasis, 1117
for tuberculosis, 1351
in tuberculin assay, vs. skin test, in HIV infection, 144
in vaginal challenge with *Candida albicans* antigen, 728
Interleukin(s)
guanylhydrazone effects on, 1303
in meningitis, *Cryptococcus neoformans*, in HIV infection, 1633
in Schwann cell damage, in Guillain-Barré syndrome, S169, S173
for tuberculosis, 1351
Interleukin-1, in HIV infection, tenidap effects on, 807
Interleukin-1α, in HIV replication, inhibition by protease inhibitors, 1175
Interleukin-1β
in HIV replication, inhibition by protease inhibitors, 1175
in pneumococcal pneumonia, mouse model, 439
in T cell activation, in malaria, 233
Interleukin-1 receptor antagonist, vs. HIV load, 1621
Interleukin-2
in *Onchocerca volvulus* infections, 838
in rhinovirus infections, 755
in vaginal challenge with *Candida albicans* antigen, 728
Interleukin-2 soluble receptor, in *Onchocerca volvulus* infections, 838
Interleukin-4
Aspergillus fumigatus conidia induction, 1579
inhibition, in antifungal therapy, mouse model, 217
in macrophage deactivation, in *Tropheryma whippelii* culture, 672, 752
in respiratory syncytial virus vaccination, mouse model, 560
Interleukin-5
in *Onchocerca volvulus* infections, 838
in respiratory syncytial virus vaccination, mouse model, 560
Interleukin-6
in *Aspergillus fumigatus* infections, 300
in HIV infection
tenidap effects on, 807
vs. viral load, 1621
vs. viral replication, inhibition by protease inhibitors, 1175
in pneumococcal pneumonia, mouse model, 439
in sepsis, in leukocytopenia, 825
Interleukin-6 soluble receptor, in sepsis, in leukocytopenia, 825
Interleukin-8, in *Aspergillus fumigatus* infections, 300
Interleukin-10
Aspergillus fumigatus conidia induction, 1579
for bacteria meningitis, rabbit model, 1239
in chronic Epstein-Barr virus infection, 254, 1454
in pneumococcal pneumonia, mouse model, 439
in T cell activation, in malaria, 233
Interleukin-12
in antifungal therapy, mouse model, 217
in T cell activation, in malaria, 233
in vaginal challenge with *Candida albicans* antigen, 728
Interstitial nephritis, chronic, *Escherichia coli* virulence factors in, 158
Intestine, bacterial translocation from, rat model, 1293
Ion transport, in cryptosporidiosis, in immunodeficiency, mouse model, 834
Isoniazid, resistance to, 722, 1125
Isoscutellarein, for pandemic influenza, S56
Isosporiasis, in HIV infection, mortality from, 632
Itraconazole, for esophageal candidiasis, in immunodeficiency, 227

Japanese encephalitis, vaccination, 1366
JC virus
detection, in human urine, 1618
genotypes, in progressive multifocal leukoencephalopathy, 1
humoral immune response to, 250
lymphocyte infection with, 1603
Joint infections, *Staphylococcus aureus*, vs. collagen-binding protein type, 1096

Kaposi's sarcoma, in HIV infection
human herpesvirus 8 DNA detection in, 84, 94, 541
treatment, interferon-α2a, 811
Kaposi's sarcoma–associated herpes virus (*See* Human herpesvirus 8)
katG gene, *Mycobacterium tuberculosis*, in isoniazid resistance, 1125
KatG(S315T) catalase-peroxidase, recombinant, *Mycobacterium tuberculosis*, isoniazid activity, 722
Kawasaki disease, immunotherapy for, 549
Keratitis, herpes simplex virus, vaccination for, mouse model, 331
Kidney, infections, *Escherichia coli*, virulence factors, 158, 464

Lactate dehydrogenase levels, in *Mycobacterium avium* complex infections, in HIV infection, 126
Lacto-*N*-neotetraose and derivatives, in *Streptococcus pneumoniae* infection inhibition, rabbit model, 704
Lamivudine, for HIV infection, 398
in combination therapy, 510
resistance to, 398
stavudine with, 1156
zidovudine and quinoxaline HBY 097 with, 1392
Laryngotracheobronchitis (croup), hospitalizations for, epidemiology, 1423
Latent membrane protein-1, mutations, Epstein-Barr virus, 1370
Legionella pneumophila, infections, tumor necrosis factor depletion in, rat model, 1019
Leishmaniasis
cutaneous, mouse model, 1649
visceral, treatment, interferon-gamma with antimony, 1117
Leprosy, lepromatous, susceptibility to, tumor necrosis factor promotor polymorphism and, 530
Leukemia, Norwegian scabies in, 1090
Leukocytopenia, sepsis in, interleukin-6 and soluble receptor dynamics in, 825
Leukoencephalitis, varicella-zoster virus, in HIV infection, 1080
Leukoencephalopathy, progressive multifocal (*See* Progressive multifocal leukoencephalopathy)
Lewis blood type, recurrent vaginal candidiasis and, 828
Licochalcone analogs, for malaria, rodent model, 1327
Lip, herpes simplex virus infections, treatment with undecylenic acid, 78
Lipid A, *Campylobacter jejuni* lipopolysaccharides, S115
Lipooligosaccharide, interleukin-10 modulation, rabbit model, 1239
Lipopolysaccharide (endotoxin)
Campylobacter jejuni
characteristics, S115, S135
molecular mimicry with gangliosides, S144, S150
hypersusceptibility to, in neonates, mouse model, 168
interleukin-1 production from, rat model, 1313
intraportal, pulmonary effects, rat model, 1293
Staphylococcus aureus delta-toxin action with, 1531
viral infection interplay with, mouse model, 151
Listeria monocytogenes, meningitis, interleukin-10 effects on, rabbit model, 1239
Liver
biopsy, hepatitis C virus RNA detection in, in cryptogenic chronic hepatitis, 27
interleukin-1 in, in endotoxemia and bacteremia, rat model, 1313

transplantation
cytomegalovirus infection after, 1135, 1484
Epstein-Barr virus infection in, lymphoproliferative disease after, 1462
human herpesvirus 6 after, 1135
Lung
enteric bacterial translocation effects on, rat model, 1293
host defenses, in *Legionella pneumophila* infections, tumor necrosis factor depletion and, rat model, 1019
interleukin-1 in, in endotoxemia and bacteremia, rat model, 1313
Lyme disease
pathogen neural cell adherence in, 470
serologic tests for, costs, in Maryland, 819
Lymph nodes
CD4 T cells in, in HIV infection, 1378
HIV in
vs. other lymphoid tissue, 804
vs. plasma, 1388
Lymphadenopathy
in *Bartonella henselae* infections, cat model, 206
in human T cell lymphotropic virus infections, 1468
Lymphedema, in *Wuchereria bancrofti* infections, 242
Lymphocyte function-associated antigen-1, expression, in cytomegalovirus retinitis, in HIV infection, 790
Lymphocyte proliferation assay, hepatitis C virus antigens, in seronegative spouses, 518
Lymphocytic choriomeningitis virus, infections, lipopolysaccharide interplay with, mouse model, 151
Lymphoid tissue
human immunodeficiency virus distribution in, 804
simian immunodeficiency virus distribution in, 804
Lymphoma
Epstein-Barr virus in, 1370
gastric, in *Helicobacter pylori* infections, 1641
Norwegian scabies in, 1090
Lymphoproliferation assay, for human immunodeficiency virus, in semen, 960
Lymphoproliferative disease, Epstein-Barr virus-associated
anti-interleukin-10 antibodies in, 1454
in liver transplantation, 1462
Lysozyme, in mucosal fungal defense, vs. antileukoprotease, 740

M protein stereotyping, for streptococci, group A, 992
Macrophage(s)
alveolar, tumor necrosis factor effects on, in *Legionella pneumophila* infection, rat model, 1019
Bordetella pertussis binding to, 678
deactivation, in *Tropheryma whippelii* culture, 672, 752
interleukin-1 production in, in endotoxemia and bacteremia, rat model, 1313
in semen, HIV in, 960
in virulent *Mycobacterium tuberculosis* inhibition, nitric oxide production and, 1552
Macrophage inhibitory protein-1α, vs. HIV load, 1621
Major outer-membrane protein, *Chlamydia trachomatis*, in vaccination, mouse model, 1035
Malaria
$\gamma\delta$ T cell activation in, cytokine-antigen interaction in, 233
prophylaxis for
in pregnancy, fetal effects, 831
tetanus-diphtheria vaccination during, lymphocyte response in, 1644
treatment
CGP 56697, 1113
2,4-dimethoxy-4'-butoxychalcone, rodent model, 1327
immunotherapy for, 549
Malnutrition, in pregnancy, enterovirus infections and, mouse model, 41
Marburg virus, research on, 1058
MDCK cells, influenza vaccine from, S20
Measles virus
antisense-mediated resistance in, 258
vaccination for, monkey model, 1445
MEDI-493 monoclonal antibody, respiratory syncytial virus, 1215
Mefloquine, in pregnancy, fetal effects, 831
Meiklejohn, G, 311
Meningitis
bacterial, interleukin-10 effects on, rabbit model, 1239
Cryptococcus neoformans, in HIV infection, 1633
group B streptococcal, hippocampal neuron apoptosis in, rat model, 693
Mycobacterium bovis, swine model, 1559
Neisseria meningitidis, serogroup C, molecular epidemiology, 1277
varicella-zoster virus, in HIV infection, 1080
Meningococcal infections, serogroup C, molecular epidemiology, 1277
Meningococcemia
fulminant, 1285
serogroup C, molecular epidemiology, 1277
Methylprednisolone, in liver transplantation, cytomegalovirus infection risk in, 1484
Microfilariasis, *Wuchereria bancrofti*, transmission, 242
β_2-Microglobulin, measurement, in progression prediction, 1161
Microneutralization assay
for parainfluenza virus type 1 hemagglutinin-neuramidase protein, 867
for respiratory syncytial virus monoclonal antibody activity, 1215
Microtubules, *Escherichia coli* invasion, 158
Middle ear pressure, in influenza, zanamivir effects on, 1417
Milk, *Escherichia coli* O157:H7 infections from, 815
Miller-Fisher syndrome, after *Campylobacter* infections, S99, S150
Minocycline, urinary catheters coated with, 1109
Mismatch assay, RNA/RNA, for rifampin resistance, 533
Mitochondrial viability, vs. HIV clone, disease progression and, 933
Molecular mimicry, in Guillain-Barré syndrome, S144, S150, S154
Monoclonal antibody(ies)
cytomegalovirus, 59
for disease treatment, 549
heteropolymers based on, in tumor necrosis factor binding to erythrocytes, 1041
parainfluenza virus type 1 hemagglutinin-neuramidase protein, 867
respiratory syncytial virus, 1215
Monocyte chemoattractant protein-1
in *Aspergillus fumigatus* infections, 300
vs. HIV load, 1621
Monocytes
anticryptococcal activity, in HIV infection, 537
Bordetella pertussis binding to, 678
cytokine production in, guanylhydrazone effects on, 1303
Ehrlichia infections, 1405
HIV expression in, pathogen effects on, 485
Mononuclear cells
hepatitis C virus RNA detection in, 1209
lymph node, HIV distribution in, 804
Morphine, in sepsis induction, mouse model, 183
Mortality, in HIV infection
from opportunistic infections, 632
prediction, 1161

RNA levels after seroconversion and, 798
Mosaic protein enzyme immunoassay, for hepatitis E virus, 34
Mosquitoes, in *Wuchereria bancrofti* transmission, 242
Mucosal immunity, to fungi, antileukoprotease in, 740
Mucous membranes, in HIV infection, herpes simplex virus infections, treatment, 892
Multiantigen immunoassay, for *Streptococcus pneumoniae* antibodies, 526
Mutations
cytomegalovirus, multidrug resistance in, 786
DNA polymerase, cytomegalovirus resistance, 69
hepatitis B virus
after vaccination, 427
vaccine failure from, 1360
human immunodeficiency virus, in didanosine-hydroxyurea combination therapy, 899
influenza virus, S14
influenza virus hemagglutinin, S24
latent membrane protein-1, Epstein-Barr virus, 1370
Mycobacterial infections, nontuberculous, in HIV infection, mortality from, 632
Mycobacterium avium complex
infections, in HIV infection
bacteremia, treatment, 1225
genotyping, 976
prior tuberculosis effects on, 1412
prophylaxis, 126
resistance in, 1225
Mycobacterium bovis, infections, swine model, 1559
Mycobacterium tuberculosis (*See also* Tuberculosis)
antigens, detection in preclinical tuberculosis, in HIV infection, 133
C strain (drug-susceptible), epidemiology, New York City, 478
drug resistance in, 533, 1125
KatG(S315T) catalase-peroxidase, isoniazid activity, 722
natural resistance to, 547
virulent, inhibition with macrophages, nitric oxide production and, 1552
Mycoplasma pneumoniae, polymerase chain reaction for, 1124

Nasopharyngeal carcinoma, anti-interleukin-10 antibodies in, 1454
Nausea and vomiting, in cyclosporiasis, clinical features vs. histopathology in, 1584
Necrosis, in clostridial gas gangrene, mouse model, 189
Necrotizing fasciitis, streptococcal group A, epidemiology, North Carolina, 992
Neisseria gonorrhoeae
infections, detection, self-administered methods for, 289
resistance in, 1269
Neisseria meningitidis
blood-brain barrier penetration by, 1285
serogroup C, molecular epidemiology, 1277
virulence factors, 1285
Neonatal infections
group B streptococcal meningitis, rat model, 693
hepatitis B virus, 427
hepatitis G virus, transmission, 281
human immunodeficiency virus, 414
antibody-dependent cellular cytotoxicity in, 643
septic shock in, endotoxin hypersusceptibility in, mouse model, 168
Neopterin, measurement, in progression prediction, 1161
Nephritis, interstitial, chronic, *Escherichia coli* virulence factors in, 158
Nerve roots, cytomegalovirus infection, diagnosis, 348
NeuAc2en, for influenza, S62
Neural cells, *Borrelia burgdorferi* adherence to, 470
Neuraminidase inhibitors, for influenza, S56, S62
Neurons, hippocampal, apoptosis, in group B streptococcal meningitis, rat model, 693
Neuropathy, in Guillain-Barré syndrome, S92, S99
Neutralization, antibody
in *Chlamydia trachomatis* infections, mouse model, 713
in HIV infection, 924, 1180
in human papillomavirus infection, monkey model, 1141
in infectious disease, 549
in parainfluenza virus infections, 867
Neutralization assay
for human immunodeficiency virus, 1410
for parainfluenza virus type 1 hemagglutinin-neuramidase protein, 867
for respiratory syncytial virus monoclonal antibody activity, 1215
Neutropenia, sepsis in, interleukin-6 and soluble receptor dynamics in, 825
Neutrophil(s)
alveolar, tumor necrosis factor effects on, in *Legionella pneumophila* infection, rat model, 1019
in *Candida albicans* hyphae destruction, 1567
hepatitis C virus RNA in, 20
Neutrophil oxidative burst, *Staphylococcus aureus* delta-toxin stimulation, 1531
Nevirapine, for HIV infection, in combination therapy, 510, 1388
NFκB, in HIV expression, 485
Nitric oxide, virulent *Mycobacterium tuberculosis* inhibition and, 1552
Nitric oxide inhibitors, cytokine production effects, 1303
Norwegian scabies, as adult T cell leukemia/lymphoma marker, 1090
Nosocomial infections
adenovirus 35 pneumonia, 760
Clostridium difficile diarrhea, outbreaks, 1233
gastroenteritis, small round-structured viruses in, 1374
multidrug-resistant tuberculosis, 748
in HIV infection, 637
Nramp1 gene, in macrophages, virulent *Mycobacterium tuberculosis* inhibition and, 1552
Nucleoprotein, measles virus, in vaccine, monkey model, 1445
Nucleoprotein-expressing DNAs, in influenza vaccine preparation, S50
Nursing homes, infectious diseases in, 1053

Oligosaccharides
core, *Campylobacter jejuni*, S115
in *Streptococcus pneumoniae* infection inhibition, rabbit model, 704
Onchocerca volvulus
infection, cytokine response in, 838
pathogenesis, rat model, 1334
Oocysts, *Cryptosporidium parvum*, in drinking water, 1120
Opsonophagocytosis, impaired, in cross-reactive *Streptococcus pneumoniae* antibodies, after vaccination, 698
Organ culture, in T cell generation studies, in HIV infection, 649
Osteomyelitis, *Staphylococcus aureus*, vs. collagen-binding protein type, 1096
Otitis media, treatment, cephalosporins, 1253
Outbreaks
adenovirus 35 pneumonia, in psychiatric facility, 760
Clostridium difficile diarrhea, 1233
cryptosporidiosis, Italy, 969
Ebola virus, 1058
Escherichia coli O39:NM infections, 1625
gastroenteritis, small round-structured viruses in, The Netherlands, 1374

sporotrichosis, tree nursery workers, 499
Streptococcus pneumoniae conjunctivitis, 1401
swine flu, S69
tuberculosis, control, 547
Outer-membrane proteins
Chlamydia trachomatis, in vaccination, mouse model, 1035
Escherichia coli J5, immunoglobulin G binding to, 1260
Oxamniquine, for *Schistosoma mansoni* infection, 304
Oxidative burst
Candida albicans hyphae destruction in, 1567
Staphylococcus aureus delta-toxin stimulation, 1531
Oxidative damage, T cell, in HIV infection, 655

P_2 protein
in experimental allergic neuritis, rat model, S160, S164
in Guillain-Barré syndrome, S160
Pandemic influenza
antivirals for, S83
Asian (1957), S8, S29
biologic origins, S8, S14
clinical issues, S85
control, antiviral agents in, S32
geographic origins, S8, S14
Hong Kong (1968–1969), S8, S29
immunologic aspects, S76
molecular aspects, S78
predictions for, S14
preparation for (*See also* Influenza, vaccination)
priority areas, S4
recommendations, S1, S87
United States, S4
research agenda for, S29
Russian (1977), S8
Spanish (1918), S8, S29
study design for, S85
surveillance for, S8, S73
viral subtypes, S14
viral transmission in, S14
Parainfluenza virus
infections, croup hospitalizations in, 1423
type 1, hemagglutinin-neuramidase protein of, characteristics, 867
Parvovirus B19, infections, in HIV infection, anemia in, 269
Pediatric patients (*See also* Neonatal infections)
croup in, hospitalizations in, 1423
dengue virus infections in, 313, 322
hepatitis B virus
carriage in, 427
vaccination in, failure, 1360
Japanese encephalitis vaccination in, 1366
malaria in, treatment, 1113
otitis media in, treatment with cephalosporins, 1253
pertussis vaccination evaluation in, 456
pneumococcal vaccination in, 445
varicella-zoster virus infections in, in HIV infection, 1496
Pelvic inflammatory disease
cytomegalovirus, 286
herpes simplex virus, 286
Penicillin, resistance to, 1269
Penis, human papillomavirus DNA, cervical neoplasia related to, 353
Peripheral blood mononuclear cells
hepatitis C virus RNA in, 20
human herpesvirus 8 DNA in, 84
human immunodeficiency virus in, vs. serum loads, 1383
Peripheral neuropathy, in Guillain-Barré syndrome, S92
Peritonitis, bacterial, in pregnancy, enterovirus infections and, mouse model, 41
Pertussis
monocyte and macrophage function in, 678
treatment, immune globulin for, 549
vaccination, evaluation, 456
Peru-15 cholera vaccine, evaluation, 201
Phagocytosis
alveolar, intraportal lipopolysaccharide effects on, rat model, 1293
impaired, in cross-reactive *Streptococcus pneumoniae* antibodies, after vaccination, 698
Pharyngitis, streptococci group A, invasive disease from, 177
Pheochromocytoma cells, *Borrelia burgdorferi* adherence to, 470
Phosphotransferase, UL97 gene, mutations in, cytomegalovirus resistance in, 69
PilC protein, in *Neisseria meningitidis* virulence, 1285
Pili, *Neisseria meningitidis*, in blood-brain barrier penetration, 1285
Placenta, enterovirus infection effects on, mouse model, 41, 1437
Plaque reduction assay, for respiratory syncytial virus monoclonal antibody activity, 1215
Plasma, hepatitis C virus RNA distribution in, 20, 27
Plasma exchange
in Guillain-Barré syndrome, S99
in HIV infection, viral load after, 801
Plasminogen activator, stimulation, *Staphylococcus aureus* in, 1637
Plasmodium berghei, infections, treatment, rodent model, 1327
Plasmodium falciparum
infections, treatment
CGP 56697, 1113
rodent model, 1327
resistance in, mutations and, 1590
schizont-associated antigen, in T cell activation, 233
Plasmodium yoelii, infections, treatment, rodent model, 1327
Platelets, hepatitis C virus RNA in, 20
Pneumococci (*See Streptococcus pneumoniae*)
Pneumocystis carinii, immunization, mouse model, 1322
Pneumocystosis, in HIV infection, mortality from, 632
Pneumonia
adenovirus 35, outbreak in psychiatric facility, 760
cytomegalovirus, in bone marrow transplantation, 778
in human T cell lymphotropic virus infections, 1468
measles virus, vaccination for, monkey model, 1445
pneumococcal, mouse model, 439
Streptococcus pneumoniae, progression, rabbit model, 704
Pneumonitis, mouse, *Chlamydia trachomatis* vaccination in, 1035
pol gene, human immunodeficiency virus, mutations, in didanosine-hydroxyurea combination therapy, 899
Poliomyelitis, vaccination
retroviral contamination in, 545
virus escape in, 617
Polioviruses, wild, genetic analysis of, The Netherlands, 617
Polymerase chain reaction
arbitrarily primed, for *Clostridium difficile*, 1233
BOX, for *Streptococcus pneumoniae* conjunctivitis, 1401
for *Campylobacter*, S106
for CCR-5 chemokine receptor alleles, in HIV infection, 1093
for *Chlamydia pneumoniae*, in carotid endarterectomy specimen, 292
for cytomegalovirus, 782
baboon vs. human, 1476
in liver transplantation, 1484
for *Ehrlichia*, 1029
for human herpesvirus 8, 771, 775
for human immunodeficiency virus, in semen, 941, 960
for human papillomavirus, in pregnancy, 277

for JC virus genotyping, 1
for *Mycoplasma pneumoniae*, 1124
reverse transcription
for hepatitis C, 20, 27
for hepatitis C virus RNA, 1209
for hepatitis G, 421
for human herpesvirus 8, 84
for rubella virus molecular epidemiology, 602
for sexually transmitted diseases, from self-collected specimens, 289
for shigellosis epidemiology, Thailand, 1013
for simian virus 40, 1618
for *Staphylococcus aureus* collagen-binding protein, 1096
for streptococci, group A, 992
for *Tropheryma whippelii*, 672, 752
for varicella-zoster virus, in HIV infection, 1080
Polymorphonuclear neutrophils, in *Candida albicans* hyphae destruction, 1567
Polyneuropathies
acute immune, *Campylobacter* and, S154
demyelinating, anti-tubulin antibodies in, S157
Polyomavirus(es), detection, in human urine, 1618
Polyomavirus JC, genotypes, in progressive multifocal leukoencephalopathy, 1
Polyradiculoneuropathy, demyelinating (*See* Guillain-Barré syndrome)
Polyradiculopathy, cytomegalovirus, diagnosis, 348
Portal vein, lipopolysaccharide in, pulmonary defense suppression in, rat model, 1293
Pott's disease, in "Tiny Tim" skeletal remains, 1653
Praziquantel
resistance to, 304
for *Schistosoma mansoni* infection, 304
Pregnancy
enterovirus infections in, mouse model, 41, 1437
hepatitis B virus infections in, transmission to infants, 1360
human immunodeficiency virus infection in
with hepatitis C, 414
transmission, 643
human papillomavirus infection in, latent, 277
mefloquine prophylaxis in, fetal effects, 831
Primaquine, prophylactic, tetanus vaccination response during, 1644
Progressive multifocal leukoencephalopathy
in HIV infection
lymphocyte infection in, 1603
mortality from, 632
humoral immune response in, 250
JC virus genotypes in, 1
lymphocyte infection in, 1603
Prophylaxis
cytomegalovirus infections, in HIV infection, 786
malaria
mefloquine for, in pregnancy, 831
tetanus-diphtheria vaccination during, lymphocyte response in, 1644
Mycobacterium avium complex infections, in HIV infection, 126
Prostatitis, *Escherichia coli*, virulence factors, 464
Protease(s), *Aspergillus fumigatus*, pathogenicity, 300
Protease inhibitors
endogenous, antifungal activity, 740
in HIV infection, mechanism of action, 1175
Pseudomonas aeruginosa, pulmonary infections, intraportal lipopolysaccharide effects on, rat model, 1293
Pyelonephritis, *Escherichia coli*, virulence factors, 464
Pyrimethamine-sulfadoxine, *Plasmodium falciparum* resistance to, 1590

QAKWRLQTL peptide, in immediate-early *trans*-activator protein BZLF1, cytotoxic T cell response to, 1068
Quinoxaline HBY 097, for HIV infection, zidovudine and lamivudine with, 1392

Radiculomyelitis, varicella-zoster virus, in HIV infection, 1080
Radioimmunofocus inhibition test, for hepatitis A virus antibodies, in vaccine evaluation, 9
Radioimmunoprecipitation assay
for *Haemophilus influenzae* antibodies, 1247
for hepatitis A virus antibodies, in vaccine evaluation, 9
RAKFKQLLQ peptide, in immediate-early *trans*-activator protein BZLF1, cytotoxic T cell response to, 1068
Random amplified polymorphic DNA analysis, *Campylobacter jejuni*, in Guillain-Barré syndrome, 1105
RANTES, vs. HIV load, 1621
Recombinant protein enzyme immunoassay, for hepatitis E virus, 34
Red blood cells
hepatitis C virus RNA in, 20
tumor necrosis factor binding to, 1041
Research, Ebola virus, 1058
Resistance, to drugs (*See* Drug resistance)
Respiratory burst
monocytes, impaired, in HIV infection, 537
Staphylococcus aureus delta-toxin stimulation, 1531
Respiratory infections (*See also* Pneumonia; Tuberculosis)
Aspergillus fumigatus, pathogenic factors, 300
enteric bacterial translocation effects on, rat model, 1293
parainfluenza virus, croup hospitalizations in, 1423
Respiratory syncytial virus
infections, immune globulin for, 549
monoclonal antibodies to, 1215
vaccination, 1428
mouse model, 560, 884
Respiratory tract, streptococci group A colonization, invasive disease from, 177
Restriction enzyme analysis, for *Clostridium difficile*, 1233
Restriction fragment length polymorphism analysis
Campylobacter jejuni, in Guillain-Barré syndrome, S129, 1105
cytomegalovirus, baboon vs. human, 1476
Mycobacterium avium complex, in HIV infection, 976
Retina, pathology, from *Onchocerca volvulus* antigens, rat model, 1334
Retinitis, cytomegalovirus, in HIV infection, 790, 1146
treatment, 50
Rhinoviruses
pathogenicity, intercellular adhesion molecule 1 in, 523
T cell response to, 755
Ribavirin
for hepatitis G virus infections, 421
for pandemic influenza, S56
Rifampin
resistance to, 533
urinary catheters coated with, 1109
Rimantadine, for pandemic influenza, S32, S56, S83
Ritonavir, in HIV infection, mechanism of action, 1175
River blindness
cytokine response in, 838
pathogenesis, rat model, 1334
RNA, hepatitis C virus, distribution in blood and blood cell fractions, 20
RNA/RNA mismatch assay, for rifampin resistance, 533
Rotavirus, vaccination, tetravalent, serologic correlates, 570
Rubella virus, E1 gene, epidemiology, East Asia, 602

S gene, hepatitis B virus, variations in, 851

Saccharides, size of, in pneumococcal vaccines, 445
Saccharomyces cerevisiae, in human papillomavirus vaccine preparation, monkey model, 1141
Saliva, human herpesvirus 8 DNA detection in, in Kaposi's sarcoma, 94
Saquinavir, for HIV infection
in combination therapy, 510
drug interactions, 265
Sarcoma, Kaposi's (*See* Kaposi's sarcoma)
Scabies, Norwegian, as adult T cell leukemia/lymphoma marker, 1090
Schistosoma haematobium, infections, antischistosome immunoglobulin detection after, 1344
Schistosoma mansoni
infections, treatment, 304
resistance in, 304
Schizont-associated antigen, *Plasmodium falciparum*, in T cell activation, 233
Schwann cell damage, in Guillain-Barré syndrome, S169, S173
Secretor status, recurrent vaginal candidiasis and, 828
Semen, human immunodeficiency virus in
distribution among cells, 960
factors affecting, 941
human herpesvirus 8 absence in, 775
Sensitization, to lipopolysaccharide, in viral infections, mouse model, 151
Sensory neuropathy, in Guillain-Barré syndrome, S99
Sepsis
bacteremia prediction rules in, 1538
coagulation prevention in, baboon model, 296
in enteric bacterial translocation, rat model, 1293
in leukocytopenia, interleukin-6 and soluble receptor dynamics in, 825
Septic arthritis, *Staphylococcus aureus*, vs. collagen-binding protein type, 1096
Septic shock
endotoxin hypersusceptibility in, mouse model, 168
in leukocytopenia, interleukin-6 and soluble receptor dynamics in, 825
morphine induction, mouse model, 183
tumor necrosis factor–erythrocyte binding and, 1041
Seroconversion
human herpesvirus 6, after liver transplantation, 1135
human immunodeficiency virus infection
RNA levels after, mortality and, 798
symptoms vs. prognosis, 112
spontaneous, in chronic hepatitis B, positive-to-negative, 845
Sexually transmitted diseases, detection, self-administered methods for, 289
Shigellosis, epidemiology, Thailand, 1013
Shingles (zoster)
in HIV infection
in pediatric patients, 1496
treatment, 103
severity, after varicella-zoster virus vaccination, in bone marrow transplantation, 578
Shock, septic
endotoxin hypersusceptibility in, mouse model, 168
in leukocytopenia, interleukin-6 and soluble receptor dynamics in, 825
morphine induction, mouse model, 183
tumor necrosis factor–erythrocyte binding and, 1041
Simian immunodeficiency virus
infections
prophylaxis, immunotherapy for, 549
treatment with cyclosporine, rhesus monkey model, 374
virus burden and distribution in, macaque model, 1198
poliomyelitis vaccine contamination with, 545
Simian immunodeficiency virus-HIV chimeric infections, macaque model, 362
Simian virus 40, detection studies in human urine, 1618
Skin lesions
herpes simplex virus, in HIV infection, treatment, 892
Sporothrix schenckii, tree nursery workers, 499
varicella-zoster virus, in HIV infection, 261
Skin tests
for HIV infection, 1085
tuberculin, vs. tuberculin interferon-γ assay, in HIV infection, 144
tuberculosis, 1351
Small round-structured viruses, gastroenteritis, epidemiology, The Netherlands, 1374
Sodium transport, in cryptosporidiosis, in immunodeficiency, mouse model, 834
Soft tissue infections, streptococcal group A, epidemiology, North Carolina, 992
Soluble egg antigen, *Schistosoma haematobium*, response to, 1344
Sorivudine, for herpes zoster, in HIV infection, 103
Southern blot test, cytomegalovirus, baboon vs. human, 1476
Sphagnum moss, sporotrichosis from, 499
Spine, tuberculosis, in "Tiny Tim" skeletal remains, 1653
Spleen, interleukin-1 in, in endotoxemia and bacteremia, rat model, 1313
Sporotrichosis, epidemiology, tree nursery workers, 499
Staphylococcal infections, immunotherapy for, 549
Staphylococcus aureus
bacteremia, prediction rules for, 1538
capsular polysaccharide
carbon dioxide regulation, 431
type vs. clinical features, 1096
collagen-binding protein, type vs. clinical features, 1096
delta-toxin, in neutrophil oxidative burst stimulation, 1531
in plasminogen activator stimulation, 1637
virulence factors, 984, 1637
von Willebrand factor interaction with, 984
Stavudine, lamivudine with, for HIV infection, 1156
Stomach, lymphoma, in *Helicobacter pylori* infections, 1641
Streptococci
group A
genotyping, 177
tissue reservoirs for, 177
infections
group A, epidemiology, North Carolina, 992
group B, meningitis, hippocampal neuron apoptosis in, rat model, 693
immunotherapy for, 549
Streptococcus mitis, resistance in, 1001
Streptococcus oralis, resistance in, 1001
Streptococcus pneumoniae
antibodies, multiantigen immunoassay for, 526
colonization, prevention with oligosaccharides, rabbit model, 704
nonserotypeable, conjunctivitis, 1401
pneumonia
mouse model, 439
progression, rabbit model, 704
resistance in, 1001
vaccination
cross-reactive antibodies with low opsonophagocytic activity in, 698
in elderly persons, 1100

in infants, 445
Superinfection, HIV (type 2), baboon model, 948
Superoxide dismutase adaptive induction, in T cell damage, in HIV infection, 655
Surfactants, cationic, in hepatitis C virus RNA detection, 20, 27
Surveillance
for Guillain-Barré syndrome, after *Campylobacter* infections, S198
pandemic influenza, S8, S73
Swine influenza
epidemiology, veterinarians, 1414
vaccination program for, S69
Syphilis, in HIV infection, false-negative serologic test results in, 1397

T cell leukemia/lymphoma, adult, Norwegian scabies in, 1090
T cells
CD4
Bordetella pertussis inhibition, 678
destruction
in chimeric simian immunodeficiency virus–HIV infection, macaque model, 362
in simian immunodeficiency virus infection, rhesus monkey model, 374
in HIV infection
asymptomatic, 665
immune globulin effects on, 913
in lymph nodes, in HIV infection, 1378
CD8 (*See also* T cells, cytotoxic)
in cytomegalovirus retinitis, in HIV infection, 790
in HIV infection type 2 defense, baboon model, 948
CD28, in cytomegalovirus retinitis, in HIV infection, 790
cytokines from
guanylhydrazone effects on, 1303
in Schwann cell damage, in Guillain-Barré syndrome, S169
cytotoxic (*See also* T cells, CD8)
in hepatitis C, 859
in HIV infection, macaque model, 1188
HIV type 1–specific, protective role, 118
response to BZLF1 immediate-early *trans*-activator protein, in Epstein-Barr virus infections, 1068
destruction, in HIV infection
from oxidative damage, 655
vs. phenotype, 933
in experimental allergic neuritis, S160
$\gamma\delta$
activation, in malaria, cytokine-antigen interaction in, 233
in leishmaniasis, mouse model, 1649
in Guillain-Barré syndrome, S160
helper
in *Candida albicans* infections, mouse model, 217
in hepatitis C, 859
in HIV infection, macaque model, 1188
in respiratory syncytial virus vaccination, mouse model, 560
response to vaginal challenge with *Candida albicans* antigen, 728
in hepatitis C, in seronegative persons, 859
interferon-γ production by, in asymptomatic viral infections, mouse model, 151
JC virus infection, 1603
peripheral blood, diminished generation in HIV infection, 649
in rhinovirus infections, 755
in semen, HIV in, 960
subsets, in HIV infection, in cytomegalovirus retinitis, 790
Tampon specimen, for sexually transmitted disease detection, 289
3TC (*See* Lamivudine)
Tenidap, for HIV infection, 807
Tetanus, vaccination, during malaria prophylaxis, lymphocyte response in, 1644
Tetracycline, resistance to, 1269
Tetradecyltrimethylammonium oxalate, in hepatitis C virus RNA detection, 20, 27
Tetravalent guanylhydrazone, cytokine production effects, 1303
Theiler's murine encephalomyelitis virus, infections, in pregnancy, mouse model, 41, 1437
Thymus culture, in T cell generation studies, in HIV infection, 649
"Tiny Tim" skeletal remains, tuberculosis in, 1653
Toxic shock syndrome
immunotherapy for, 549
streptococcal group A, epidemiology, North Carolina, 992
Toxins (*See also* Lipopolysaccharide (endotoxin))
clostridial, tissue necrosis from, mouse model, 189
Staphylococcus aureus, in neutrophil burst stimulation, 1531
streptococcal, group A, 992
Vibrio parahaemolyticus, 822
Toxoplasmosis, in HIV infection, mortality from, 632
Trachoma, severe, bacterial load in, in pediatric patients, 1524
Transforming growth factor, in Schwann cell damage, in Guillain-Barré syndrome, S169, S173
Translocation, bacterial, rat model, 1293
Transplantation
bone marrow
cytomegalovirus infection in
circulating infected endothelial cells in, 778
viral load in, 782
varicella-zoster virus vaccination in, 578
liver
cytomegalovirus infection after, 1135, 1484
Epstein-Barr virus infection in, lymphoproliferative disease in, 1462
human herpesvirus 6 after, 1135
nonhuman primate organs in, cytomegalovirus identification in, 1476
Travelers' diseases
hepatitis E virus infections, 34
poliomyelitis, The Netherlands, 617
Trichomonas vaginalis, infections, detection, self-administered methods for, 289
Tropheryma whippelii, culture, macrophage deactivation for, 672, 752
Trophozoites, *Entamoeba histolytica*, pathogenic mechanisms, 1597
Trypanosoma cruzi, epidemiology, United States blood donors, 1047
Tuberculin skin test, vs. tuberculin interferon-γ assay, in HIV infection, 144
Tuberculosis (*See also Mycobacterium tuberculosis*)
drug-susceptible strain, epidemiology, New York City, 478
in HIV infection, 1351
detection methods, 144
multidrug-resistant, 637, 748
Mycobacterium avium complex susceptibility in, 1412
nosocomial, 637
preclinical, antibody detection in, 133
in human T cell lymphotropic virus infections, 1468
immune response in, 1351
immunogenetics, 1351
multidrug-resistant, epidemiology
Buenos Aires, 637
global, 748
resistance in, 533
epidemiology
Buenos Aires, 637
global, 748

skin tests for, 144, 1351
spinal, in "Tiny Tim" skeletal remains, 1653
swine model, 1559
treatment
cytokines, 1351
immunotherapy, 549
molecular approach, 547
vaccination, 748, 1351
Tubulin, antibodies to, in demyelinating polyneuropathies, S157
Tumor necrosis factor(s)
antibody-mediated depletion, in *Legionella pneumophila* infections, rat model, 1019
Aspergillus fumigatus conidia induction, 1579
erythrocyte binding to, 1041
in group B streptococcal meningitis, hippocampal neuron apoptosis from, rat model, 693
guanylhydrazone effects on, 1303
in HIV infection
immune globulin effects on, 913
tenidap effects on, 807
in viral expression, 485
vs. viral load, 1621
in viral replication, inhibition by protease inhibitors, 1175
from intraportal lipopolysaccharide, rat model, 1293
in lipopolysaccharide hypersensitivity, in asymptomatic viral infections, mouse model, 151
in meningitis, *Cryptococcus neoformans*, in HIV infection, 1633
in pneumococcal pneumonia, mouse model, 439
promotor, polymorphism, lepromatous leprosy susceptibility and, 530
in Schwann cell damage, in Guillain-Barré syndrome, S173
in septic shock, mouse model, 168
Staphylococcus aureus delta-toxin action with, 1531
for tuberculosis, 1351
Tumor necrosis factor receptor
vs. HIV load, 1621
soluble, measurement, in progression prediction, 1161
Tumor necrosis factor receptor-immunoglobulin fusion protein, in coagulation prevention, baboon model, 296

UL54 gene, DNA polymerase, mutations in, cytomegalovirus resistance in, 69
UL97 gene, phosphotransferase, mutations in, cytomegalovirus resistance in, 69
Undecylenic acid, for herpes simplex labialis, 78
Urinary tract infections
in elderly persons, 1053
Escherichia coli, virulence factors, 158, 464
in human T cell lymphotropic virus infections, 1468
prevention, with antimicrobial-coated catheters, 1109
Urinary urgency, in human T cell lymphotropic virus infections, 1468
Urine
culture, cytomegalovirus, in HIV infection, 50
human, simian virus 40 detection studies on, 1618
JC virus genotypes in, 1
Urokinase-type plasminogen activator, stimulation, *Staphylococcus aureus* in, 1637
Uteroplacental blood flow disturbances, enterovirus infections and, mouse model, 41

Vaccination
Campylobacter, S183, S189
Chlamydia trachomatis, mouse model, 1035
cholera, Peru-15, 201
combined, *Streptococcus pneumoniae* with, 445
DNA-based
Chlamydia trachomatis, mouse model, 1035
HIV, chimpanzee model, 1501
influenza, S50
hepatitis A virus
antibody detection after, primate and human models, 593
in HIV infection, 1064
with inactivated vaccine, vs. immune globulin, 9
hepatitis B virus
failure, 1360
mutations after, 427
herpes simplex virus
type 1, mouse model, 331
type 2, 1129
human immunodeficiency virus
cellular immune response in, 904
chimpanzee model, 1501
clinical trials, 384
skin testing in, 1085
human papillomavirus type 11, monkey model, 1141
influenza (*See* Influenza, vaccination)
Japanese encephalitis, 1366
measles virus, monkey model, 1445
Onchocerca volvulus, rat model, 1334
passive, hepatitis A, 9
passive immunity and, 549
pertussis, 456
Pneumocystis carinii, mouse model, 1322
poliomyelitis
retroviral contamination in, 545
virus escape in, 617
respiratory syncytial virus, 1428
mouse model, 560, 884
rotavirus, tetravalent, serologic correlates, 570
Streptococcus pneumoniae
cross-reactive antibodies with low opsonophagocytic activity in, 698
in elderly persons, 1100
in infants, 445
tetanus, during malaria prophylaxis, lymphocyte response in, 1644
tuberculosis, 748, 1351
varicella-zoster virus
in bone marrow transplantation, 578
in HIV infection, 1496
virus transmission after, 1072
Varicella-zoster virus
infections, in HIV infection, 1080
chronic skin lesions in, 261
in pediatric patients, 1496
vaccination
in bone marrow transplantation, 578
in HIV infection, 1496
virus transmission after, 1072
Vascular infections, *Staphylococcus aureus*, von Willebrand factor in, 984
Vesicular stomatitis virus, infections, lipopolysaccharide interplay with, mouse model, 151
Veterinarians, swine influenza epidemiology in, 1414
Vibrio cholerae, infections, vaccination with Peru-15 vaccine, 201
Vibrio parahaemolyticus, invasive phenotype, 822
Viral infections (*See also specific infections*)
lipopolysaccharide interplay with, mouse model, 151
Viremia, dengue virus, 322
Virulence factors

Campylobacter, S122
Campylobacter jejuni, S135
Entamoeba histolytica, 1597
Escherichia coli, uropathogenic, 158, 464
Neisseria meningitidis, 1285
Staphylococcus aureus, 984, 1637
Vibrio parahaemolyticus, 822
Virus neutralization assay, for hepatitis A virus antibodies, in vaccine evaluation, 9
Visceral leishmaniasis, treatment, interferon-γ with antimony, 1117
Vitamin E supplementation, in influenza, mouse model, 273
von Willebrand factor, *Staphylococcus aureus* interaction with, 984
Vulvovaginal candidiasis, recurrent
blood type and, 828
local immunodeficiency in, 728

Waterborne diseases, cryptosporidiosis, 1120
Weight loss, in cyclosporiasis, clinical features vs. histopathology in, 1584
Western blot test
human T cell lymphotropic virus type I, 505
Lyme disease, costs, in Maryland, 819
Whipple's disease, pathogen culture in, macrophage deactivation for, 672, 752
Whooping cough (*See Bordetella pertussis*, infection)
World Health Organization, pandemic influenza surveillance program, S8, S73
Wuchereria bancrofti, infections, transmission, 242

Xenotransplantation, cytomegalovirus identification in, 1476

Yeast, in human papillomavirus vaccine preparation, monkey model, 1141

Zanamivir
for otologic manifestations, in influenza, 1417
for pandemic influenza, S56
Zidovudine, for HIV infection, 398
cellular immune response to, 904
in combination therapy, 510
didanosine and nevirapine with, 1388
hemopoiesis and, 1510
lamivudine and quinoxaline HBY 097 with, 1392
resistance to, 398, 1392
Zoonoses, antibodies in, in veterinarians, 1414
Zoster (*See* Shingles)